

Auditor's Examination Report

Independent Auditor's Examination Report on Restated Ind AS Audited Consolidated Financial Information

To

The Board of Directors

Gujarat Kidney And Super Speciality Limited,

Plot No 1, City Surve No. 1537/A,

Jetalpur Road, Gokak Mill Compound,

Alkapuri, Vadodara, 390020

1. We have examined, the attached Restated Consolidated Financial Information of **Gujarat Kidney And Super Speciality Limited** (the "Company" or "GKSL" and its subsidiary and entities under control (referred as Subsidiary Firms) (together referred to as "Group"), comprising the Restated Consolidated Statement of Assets and Liabilities as at September 30, 2024, March 31, 2024, March 31, 2023, and March 31 2022, the Restated Consolidated Statement of Profit and Loss (including other comprehensive income), the Restated Consolidated Cash Flow Statement, the Restated Consolidated Statement of Changes in Equity for the period ended on September 30, 2024 and years ended March 31, 2024, March 31, 2023 and March 31, 2022, the Summary Statement of Significant Accounting Policies, and other explanatory information (collectively, the "Restated Consolidated Financial Information"), as approved by the Board of Directors of the Company at their meeting held on 15.03.2025 for the purpose of inclusion in the Draft Red Herring Prospectus ("DRHP"), prepared by the Company in connection with its proposed Initial Public Offer of equity shares ("IPO") prepared in terms of the requirements of:
 - a. Section 26 of Part I of Chapter III of the Companies Act, 2013 (the "Act");
 - b. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended ("ICDR Regulations"); and
 - c. The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended (the "Guidance Note").
2. The Company's Board of Directors are responsible for the preparation of the Restated Consolidated Financial Information for the purpose of inclusion in the Offer Documents to be filed with the Registrar of Companies, Ahmedabad, Gujarat, Securities and Exchange Board of India, National Stock Exchange of India Limited and BSE Limited in connection with the IPO. The Restated Consolidated Financial Information has been prepared by the management of the Company on the basis of preparation stated in note no.2 to the Restated Consolidated Financial Information. The respective Board of Directors of the companies included in the Group are responsible for designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information.

The respective Board of Directors of the companies included in the Group are also responsible for identifying and ensuring that the Group/ each company within the Group complies with the Act, ICDR Regulations and the Guidance Note.



3. We have examined such Restated Consolidated Financial Information taking into consideration:
- The terms of reference and terms of our engagement agreed upon with you in accordance with our engagement letter dated 01.03.2025 in connection with the proposed IPO;
 - The Guidance Note, which also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI;
 - Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Ind AS Consolidated Financial Information; and
 - The requirements of Section 26 of the Act and the ICDR Regulations. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Companies Act, the ICDR Regulations and the Guidance Note in connection with the IPO.
4. These Restated Consolidated Financial Information have been compiled by the management from:
- The audited special purpose interim consolidated Ind AS financial statements of the Group as at and for the period ended September 30, 2024 (the "**Interim Special Purpose Consolidated Ind AS Financial Statements**") prepared in accordance with the basis and accounting policies mentioned in Note 2 to Interim Special Purpose Consolidated Ind AS Financial Statements, which have been approved by the Board of Directors at their meeting held on 15.03.2025; and
 - The audited special purpose Ind AS financial statements of the Company as at and for the years ended on March 31, 2024, March 31, 2023 and March 31, 2022 prepared in accordance with the Ind AS as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India (the "**Special Purpose Ind AS Financial Statements 2024-22**"), which have been approved by the Board of Directors at their meeting held on 15.03.2025
5. The information for the years ended March 31, 2024, March 31, 2023 and March 31, 2022, included in Restated Ind AS Consolidated Financial Information have been compiled from the Special Purpose Ind AS Financial Statements 2024-22 for the years March 31, 2024, March 31, 2023 and March 31, 2022 being prepared by the management by making all the adjustments required under the Ind AS to the audited financial statements of the Company as at and for the years March 31, 2024, March 31, 2023 and March 31, 2022 which were prepared in accordance with the accounting standards notified under section 133 of the Act ("Indian GAAP") and other accounting principles generally accepted in India, at the relevant time, which have been approved by the respective Board of Directors at their meetings held on 27.08.2024, 25.09.2023 and 03.09.2022 respectively, for the audited financial statements as at March 31, 2024, March 31, 2023 and March 31, 2022 and audited by the previous auditor, respectively.

We have audited Special Purpose Ind AS Financial Statements 2024-22 of the company for the years ended March 31, 2024, March 31, 2023 and March 31, 2022, prepared by the Company in accordance with the Ind AS for the limited purpose of consideration in preparation of Restated Ind AS Consolidated Financial Information, in relation to proposed IPO. We have issued our report dated 15.03.2025 on Special Purpose Ind AS Financial Statements 2024-22 to the Board of Directors who have approved these Special Purpose Ind AS Financial Statements 2024-22 in their meeting held on 15.03.2025.

6. For the purpose of our examination, we have relied on:

- a. Auditors' Report issued by us dated 15.03.2025 on the Special Purpose Interim Consolidated Ind AS Financial Statements of the Group as at and for the period ended September 30, 2024 as referred in Para 4 above. The auditor's report on Special Purpose Interim Consolidated Ind AS Financial Statements of the Group as at and for the period ended September 30, 2024 included the following other matter paragraph ; and

Other matter paragraph:

We did not audit the special purpose financial statements of three subsidiary and entities under control (referred as Subsidiary Firms), whose special purpose financial statements reflects total assets (before consolidation adjustments) of Rs. 834.07 Lacs as at September 30, 2024, total revenues (before consolidation adjustments) of Rs. 528.46 Lacs and net cash outflows (before consolidation adjustments) amounting to Rs. 159.14 Lacs for the period ended on that date, as considered in the special purpose consolidated financial statements. These special purpose financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the special purpose consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary and entities under control (referred as Subsidiary Firms), and our report so far as it relates to the aforesaid subsidiary and entities under control (referred as Subsidiary Firms) is based solely on the report of the other auditors.

Our Opinion is not modified in respect of this matter.

- b. the auditor's reports issued by us dated 15.03.2025 on Special Purpose Ind AS Financial Statements 2024-22 as at and for the years ended March 31, 2024, March 31, 2023 and March 31, 2022 as referred in Paragraph 4 and 5 above
- c. The auditor's report issued by previous auditor namely **Kumbhat & Co**, of the company dated 27.08.2024 on audited the Indian GAAP financial Statements as at and for the year ended March 31, 2024, as referred in Paragraph 5 above.
- d. The auditor's report issued by previous auditor namely **Vipul Shah & Co**, of the company dated 25.09.2023 on the audited the Indian GAAP financial Statements as at and for the year ended March 31, 2023, as referred in Paragraph 5 above.
- e. The auditor's report issued by previous auditor namely **Vipul Shah & Co**, of the company dated 30.09.2022 on the audited the Indian GAAP financial Statements as at and for the year ended March 31, 2022, as referred in Paragraph 5 above

7. As indicated in our audit reports referred above:

We did not audit the financial statements of three subsidiary and entities under control (referred as Subsidiary Firms) included in the Group as of and for the period ended September 30, 2024, as listed in Annexure I whose financial statements reflect total assets, total revenues and total cash flows (before consolidation adjustments) included in the Audited Consolidated Financial Statements for the relevant period as tabulated below. These financial statements have been audited by other auditor as detailed in Annexure I whose reports have been furnished to us, and our opinion, insofar as it relates to the amounts included in respect of such subsidiary and entities under control (referred as Subsidiary Firms), is based solely on the reports of such other auditor



Our opinion on the consolidated financial statements is not modified in respect of the matters above

(Rs. in Lacs)

particulars	As at / for the Period ended September 30, 2024	As at / for the Year ended March 31, 2024
Total assets	834.07	NA
Total revenues	528.46	NA
Net cash flow	159.14	NA

8. Based on our examination and according to the information and explanations given to us and also as per the reliance placed on the audit reports referred in paragraphs 6 submitted by the previous auditor of the Company and other auditors of the subsidiary and entities under control (referred as Subsidiary Firms) for the respective years, as applicable, we report that the Restated Ind AS Consolidated Financial Information:
 - a. have been prepared after incorporating adjustments for the changes in accounting policies, material errors and regrouping/reclassifications retrospectively in the financial years ended March 31, 2024 March 31, 2023 and March 31, 2022 to reflect the same accounting treatment as per the accounting policy and grouping/classifications followed as at and for the period ended September 30, 2024;
 - b. do not require any adjustment for modification as there is no modification in the underlying audit reports; and
 - c. have been prepared in accordance with the Act, the ICDR Regulations and the Guidance Note.
9. The Restated Ind AS Consolidated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the reports on the audited Ind AS Consolidated Financial Statements mentioned in paragraphs 4 and 5 above and the Special Purpose Ind AS Financial Statements.
10. This report should not in any way be construed as a reissuance or re-dating of any of the previous audit reports issued by us, or the previous auditors nor should this report be construed as a new opinion on any of the Standalone and Consolidated financial statements referred to herein.
11. We have no responsibility to update our report for events and circumstances occurring after the date of the report.



12. Our report is intended solely for use of the Board of Directors for inclusion in the DRHP to be filed with Securities and Exchange Board of India, and relevant stock exchanges in connection with the proposed IPO. Our report should not be used, referred to, or distributed for any other purpose except with our prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

Date: 15.03.2025


Place: Vadodara



FOR Y. M. SHAH & Co.

Chartered Accountants

F. R. No.: 114124W



Yogesh Shah

Partner

M. No. 044305

UDIN: 25044305BMOQMP1038

Annexure I

Entity	Nature of holding	Period/Year as of/Ended	Name of Auditor	Particulars
Raj Palmland Hospital Private Limited	Subsidiary	30 September 2024	K.K. Haryani & Co.	Audit report dated 01.03.2025 on Interim Special Purpose Ind AS Financial Statements
Gujarat Surgical Hospital	Subsidiary Firm	30 September 2024	NIRAV SHAH & ASSOCIATES	Audit report dated 01.03.2025 on Interim Special Purpose Ind AS Financial Statements
Surya Hospital and ICU	Subsidiary Firm	30 September 2024	RONAK S SHAH & ASSOCIATES	Audit report dated 01.03.2025 on Interim Special Purpose Ind AS Financial Statements



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Restated Consolidated Financial Information**Statement of Consolidated Assets and Liabilities**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Particulars	Note No	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
ASSETS					
Non-current assets					
Property, Plant and Equipment	6	1,066.12	973.84	-	267.18
Right-of-Use Assets	7	470.28	390.22	-	-
Capital work-in-progress	8	23.38	-	-	-
Financial Assets					
Other financial assets	9	34.49	5.62	-	-
Deferred tax assets net	10	33.32	2.64	4.19	4.18
Other non-current assets	11	9.90	7.35	267.18	-
Total Non-current Assets		1,637.49	1,379.67	271.37	271.36
Current assets					
Inventories	12	37.61	27.00	-	-
Financial Assets					
Trade receivables	13	1,204.70	420.17	115.00	116.07
Cash and cash equivalents	14	422.54	97.04	0.35	0.34
Bank balances	15	240.68	20.46	-	-
Other financial assets	16	4.81	0.19	-	-
Other current assets	17	116.76	108.03	-	-
Total Current Assets		2,027.10	672.89	115.35	116.41
Total Assets		3,664.59	2,052.56	386.72	387.77
EQUITY and LIABILITIES					
Equity Share Capital	18	32.19	20.00	20.00	20.00
Other Equity	19	1,884.71	1,060.43	17.02	17.65
Equity attributable to owners of the Company		1,916.90	1,080.43	37.02	37.65
Non-controlling interests	20	144.48	-	-	-
Total Equity		2,061.38	1,080.43	37.02	37.65
Non-current liabilities					
Financial Liabilities					
Borrowings	21	183.28	153.03	-	-
Lease liabilities	22	442.17	369.74	-	-
Other financial liabilities	23	5.00	-	-	-
Provisions	24	42.41	25.51	-	-
Total Non-current liabilities		672.86	548.28	-	-
Current liabilities					
Financial Liabilities					
Borrowings	25	185.37	41.35	-	-
Lease liabilities	26	54.99	22.39	-	-
Trade Payables for expenses	27	-	-	-	-
total outstanding dues of micro enterprises and small enterprises		-	-	-	-
total outstanding dues of others		367.89	240.21	346.76	346.72
Other current liabilities	28	153.19	81.20	2.94	2.92
Provisions	29	4.46	2.26	-	-
Current Tax Liabilities (Net)	30	164.45	36.44	-	0.48
Total Current liabilities		930.35	423.85	349.70	350.12
Total liabilities		1,603.21	972.13	349.70	350.12
Total Equity and Liabilities		3,664.59	2,052.56	386.72	387.77

For & on Behalf of

Y M SHAH & Co.

Chartered Accountants

FRN: 114124W

CA Yogesh Shah

Partner

Membership No. 044305

UDIN: 25044305BMOQMP1038

Place: Vadodara

Date: 15-03-2025

For and on behalf of Board of Directors,

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Pragnesh Bharpoda

Director

DIN: 01033141

Niki Tiwari

Company secretary

Anitaben Bharpoda

Director

DIN: 08644747

Bhavikaben Patel

Chief Financial Officer

GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Restated Consolidated Financial Information**Statement of Consolidated Profit & Loss**


(All amounts are ₹ in Lakhs, unless otherwise stated)

Particulars	Note No	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Income					
Revenue From Operations	31	1,867.05	477.43	-	-
Other Income	32	5.11	70.39	0.01	78.60
Total Income		1,872.16	547.82	0.01	78.60
Expenses					
Cost of medical consumables, drugs and surgical items	33	136.55	30.69	-	-
Employee benefits expense	34	341.01	107.29	-	4.80
Finance costs	35	31.57	6.72	-	-
Depreciation and amortization expense	36	151.39	31.93	-	57.40
Other expenses	37	455.64	144.36	0.63	2.73
Total Expenses		1,116.16	320.99	0.63	64.93
Profit/(loss) before tax		756.00	226.83	-0.62	13.67
Tax expense	38				
Current tax		211.40	53.88	-	5.49
Deferred tax		-18.53	1.55	-	-1.82
Total Tax expense		192.87	55.43	-	3.67
Profit/(loss) after tax for the period		563.13	171.40	-0.62	10.00
Other Comprehensive Income					
OCI that will not be reclassified to P&L	39				
(i) Remeasurements of the defined benefit plans		3.59	-	-	-
(ii) Others		22.66	-	-	-
OCI Income tax of items that will not be reclassified to P&L		-0.90	-	-	-
OCI that will be reclassified to P&L				-	-
Total Other Comprehensive Income		25.34	-	-	-
Total Comprehensive Income for the period		588.47	171.40	-0.62	10.00
Profit/(loss) after tax for the period attributable to:					
-Owners of the company		563.13	171.40	-	-
-Non-Controlling Interests		-	-	-	-
Total Other Comprehensive Income attributable to:		563.13	171.40	-	-
-Owners of the company		25.34	-	-	-
-Non-Controlling Interests		-	-	-	-
Total Comprehensive Income for the period attributable to:		25.34	-	-	-
-Owners of the company		588.48	171.40	-	-
-Non-Controlling Interests		-	-	-	-
Earnings per equity share		588.48	171.40	-	-
Basic	40	1.24	0.49	-0.00	0.03
Diluted		1.24	0.49	-0.00	0.03

For & on Behalf of
Y M SHAH & Co.
Chartered Accountants
FRN: 114124W

CA Yogesh Shah
Partner

Membership No. 044305
UDIN: 25044305BMOQMP1038
Place: Vadodara
Date: 15-03-2025



For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
CIN: U85300GJ2019PLC111559

Pragnesh Bharpoda
Director

DIN: 01033141

Niki Tiwari
Company secretary

Anitaben Bharpoda
Director

DIN: 08644747

Bhavikaben Patel
Chief Financial Officer



(Signature)

GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
CIN: U85300GJ2019PLC111559
Restated Consolidated Financial Information
Statement of change in Equity
(All amounts are ₹ in Lakhs, unless otherwise stated)

A. Equity Share Capital

Equity Share Capital	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Opening Balance for the period	20.00	20.00	20.00	20.00
Changes in Equity Share Capital due to Prior Period	-	-	-	-
Restated Balance as at	20.00	20.00	20.00	20.00
Changes in Equity Share Capital during the year	12.19	-	-	-
As at Balancesheet Date	32.19	20.00	20.00	20.00

B. Other Equity

Other Equity At 30 September 2024	Share application pending allotment	Reserves & Surplus			Other Comprehensive Income	Total
		Capital Reserve	Securities premium	Retained Earnings	Other items of OCI	
Balance as at 01 April 2024	906.37	-	-	154.05	-	154.05
Changes in Accounting Policy or Prior Period	-	-	-	-	-	-
Restated balance as at 01 April 2024	906.37	-	-	154.05	-	154.05
Add: Profit/(Loss) during the year	-	-	-	563.13	-	563.13
Remeasurement Gain/(Loss) of defined Benefit Plan	-	-	-	-	2.69	2.69
Total Comprehensive Income/(Expense)	906.37	-	-	717.18	2.69	719.87
Add: Application money received	-	-	-	-	-	-
Add: Issue of Equity Shares	-	-	1,142.18	-	-	1,142.18
Less: Allotment of Equity Shares	906.37	-	-	-	-	-
Transferred from OCI - Gain on Bargain Purchase	-	22.66	-	-	-	22.66
Gain on Bargain Purchase	-	-	-	-	22.66	22.66
Transferred to Capital Reserve - Gain on Bargain Purchase	-	-	-	-	-22.66	-22.66
Expense for increase of authorised capital	-	-	-	-	-	-
Balance as at 30 September 2024	-	22.66	1,142.18	717.18	2.69	1,884.71



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
CIN: U85300GJ2019PLC111559
Restated Consolidated Financial Information
Statement of change in Equity
(All amounts are ₹ in Lakhs, unless otherwise stated)

Other Equity At 31 March 2024	Share application pending allotment	Reserves & Surplus			Other Comprehensive Income	Total
		Capital Reserve	Securities premium	Retained Earnings	Other items of OCI	
Balance as at 01 April 2023	-	-	-	17.02	-	17.02
Changes in Accounting Policy or Prior Period Errors	-	-	-	-	-	-
Restated balance as at 01 April 2023	-	-	-	17.02	-	17.02
Net profit/(loss) during the year	-	-	-	171.40	-	171.40
Remeasurement Gain/(Loss) of defined Benefit Plan	-	-	-	-	-	-
Less: Transferred to Capital Reserve - Gain on Bargain Purchase	-	-	-	-	-	-
Total Comprehensive Income/(Expense)	-	-	-	188.42	-	188.42
Add: Application money received	906.37	-	-	-	-	906.37
Add: Issue of Equity Shares	-	-	-	-	-	-
Less: Allotment of Equity Shares	-	-	-	-	-	-
Transferred from OCI - Gain on Bargain Purchase	-	-	-	-	-	-
Gain on Bargain Purchase	-	-	-	-	-	-
Expense for increase of authorised capital	-	-	-	-34.36	-	-34.36
Balance as at 31 March 2024	906.37	-	-	154.06	-	1,060.43

Other Equity At 31 March 2023	Share application pending allotment	Reserves & Surplus			Other Comprehensive Income	Total
		Capital Reserve	Securities premium	Retained Earnings	Other items of OCI	
Balance as at 01 April 2022	-	-	-	17.65	-	17.65
Changes in Accounting Policy or Prior Period Errors	-	-	-	-	-	-
Restated balance as at 01 April 2022	-	-	-	17.65	-	17.65
Add: Profit/(Loss) during the year	-	-	-	-0.62	-	-0.62
Total Comprehensive Income/(Expense)	-	-	-	17.02	-	17.02
Balance as at 31 March 2023	-	-	-	17.02	-	17.02




GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
CIN: U85300GJ2019PLC111559
Restated Consolidated Financial Information
Statement of change in Equity
(All amounts are ₹ in Lakhs, unless otherwise stated)

Other Equity At 31 March 2022	Share application pending allotment	Reserves & Surplus			Other Comprehensive Income	Total
		Capital Reserve	Securities premium	Retained Earnings	Other items of OCI	
Balance as at 01 April 2021	-	-	-	7.65	-	7.65
Changes in Accounting Policy or Prior Period Errors	-	-	-	-	-	-
Restated balance as at 01 April 2021	-	-	-	7.65	-	7.65
Net profit/(loss) during the year	-	-	-	10.00	-	10.00
Total Comprehensive Income/(Expense)	-	-	-	17.65	-	17.65
Balance as at 31 March 2022	-	-	-	17.65	-	17.65

For & on Behalf of
Y M SHAH & Co.
Chartered Accountants
FRN: 114124W

CA Yogesh Shah
Partner

Membership No. 044305
UDIN: 25044305BMOQMP1038
Place: Vadodara
Date: 15-03-2025



For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
CIN: U85300GJ2019PLC111559

Pragnesh Bharpoda
Director
DIN: 01033141

Niki Tiwari
Company secretary



Anita

Anitaben Bharpoda
Director
DIN: 08644747

Bhavikaben Patel
Chief Financial Officer

(Signature of Bhavikaben Patel)

GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
CIN: U85300GJ2019PLC111559
Restated Consolidated Financial Information
Statement of Consolidated Cash Flow
(All amounts are ₹ in Lakhs, unless otherwise stated)

Particulars	For the period ended 30 September 2024	For Year ended 31 March 2024	For Year ended 31 March 2023	For Year ended 31 March 2022
CASH FLOWS FROM OPERATING ACTIVITIES				
Profit for the year	563.14	171.40	-0.62	10.00
Adjustments for:				
Depreciation and amortisation	151.39	31.93	-	57.40
(Gain)/Loss on disposal of property, plant and equipment	-	-70.16	-	-
(Gain)/Loss on disposal of Investments	-	-	-	-
(Gain)/Loss on investments measured at FVTPL	-	-	-	-
(Gain)/Loss on investments measured at fair value through profit and loss	-	-	-	-
Provision for Income tax	192.87	55.43	-	3.67
Gratuity Provision Expense	6.93	8.34	-	-
Finance Cost	31.57	6.72	-	-
Interest Income	-4.82	-0.18	-	-
Operating profit before working capital changes	941.08	203.48	-0.62	71.07
Adjustment for (increase) / decrease in operating assets				
Trade receivables	-568.14	18.68	1.07	-60.69
Loans & Advances	2.50	-	-	-
Other financial assets	-6.77	7.19	-	-
Inventories	-10.61	-27.00	-	-
Other assets	38.22	205.37	-	-
Adjustment for (Increase) / decrease in operating liabilities				
Trade payables	-39.28	-347.26	0.03	1.96
Employee benefit obligation	-	-	-	-
Other Liabilities	20.51	78.26	0.02	-2.18
Cash generated from operations	377.51	138.72	0.50	10.16
Income tax paid (net)	-83.38	-17.44	-0.49	-9.94
Net cash generated by operating activities	294.13	121.28	0.01	0.22
CASH FLOWS FROM INVESTING ACTIVITIES				
Bank deposits placed	-220.22	-20.46	-	-
Purchase of property, plant and equipment	-50.56	42.61	-	-
Outflow due to business acquisition	-151.45	-	-	-
Interest received	4.82	0.19	-	-
Net cash (used in) / generated by investing activities	-417.41	22.34	-	-
CASH FLOWS FROM FINANCING ACTIVITIES				
Repayment of lease liabilities	-10.92	-1.77	-	-
Proceeds from short term borrowings	70.32	-	-	-
Proceeds from long term borrowings	-56.38	-4.07	-	-
Finance cost	-31.57	-6.72	-	-
Issue of Equity Shares	248.00	-	-	-
Share Issue Expenses	-	-34.37	-	-
Net cash used in financing activities	219.45	-46.93	-	-
Net increase / (decrease) in cash and cash equivalents	96.17	96.69	0.01	0.22
Cash and cash equivalents at the beginning of the year	97.04	0.35	0.34	0.12
Cash and cash equivalents due to business acquisition	229.33	-	-	-
Cash and cash equivalents at the end of the year	422.54	97.04	0.35	0.34

For & on Behalf of
Y M SHAH & Co.
Chartered Accountants
FRN: 114124W

CA Yogesh Shah
Partner

Membership No. 044305
UDIN: 25044305BMOQMP1038
Place: Vadodara
Date: 15-03-2025



For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
CIN: U85300GJ2019PLC111559

Pragnesh Bharpoda
Director

DIN: 01033141

Niki Tiwari
Company secretary

Anitaben Bharpoda
Director

DIN: 08644747

Bhavikaben Patel
Chief Financial Officer



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

1 Group Information

M/s GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED (formerly known as GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED) (the 'Company' or 'the holding Company') incorporated on December 20, 2019 under the provisions of the Companies Act, 2013 having CIN: U85300GJ2019PTC111559. The Company's registered office is at Plot No 1, City Serve No 1537/A, Jetalpur Rd, Gokak Mill Compound, Alkapuri, Vadodara, Gujarat, India, 390020.

On 13 September 2023, the company changed its name from VIHAAN MEDICARE PRIVATE LIMITED to GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED and thereafter, the name of the Company was changed to "GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED" and a fresh certificate of incorporation consequent upon change of name was issued by the ROC on 24 November 2023.

The Restated Consolidated Financial Information comprise the restated consolidated financial information of the Holding Company, its subsidiary and entities under control (referred as Subsidiary Firms), (referred to collectively as the "Group") for the period/year as of/ ended September 30, 2024, March 31, 2024, March 31, 2023, and March 31, 2022.

The Group is a multi-specialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care. The Hospital operates with a commitment to delivering high-quality healthcare through advanced medical technology and a team of highly skilled professionals.

Subsidiary:

Name of the entity	Place of business	% of effective ownership interest held by the Group			
		30 September 2024	31 March 2024	31 March 2023	31 March 2022
Raj Palmland Hospital Private Limited	India	51.00%	0.00%	0.00%	0.00%

Subsidiary Firms:

Name of the entity	Place of business	% of effective ownership interest held by the Group			
		30 September 2024	31 March 2024	31 March 2023	31 March 2022
Gujarat Surgical Hospital	India	90.00%	0.00%	0.00%	0.00%
Surya Hospital and ICU	India	90.00%	0.00%	0.00%	0.00%

2 Basis of Preparation of Financial Statement

2.1 Basis of Preparation

The Restated Consolidated Financial Information of the Group comprise of the restated consolidated statement of assets and liabilities as at September 30, 2024, March 31, 2024, March 31, 2023 and March 31, 2022, the related restated consolidated statement of profit and loss, the restated consolidated statement of changes in equity and the restated consolidated statement of cash flows for the period ended on September 30, 2024, and years ended on March 31, 2024, March 31, 2023 and March 31, 2022, and the summary of significant accounting policies and other explanatory information (collectively, the 'Restated Consolidated Financial Information').

The Restated Consolidated Financial Information have been prepared by the management of the Company for inclusion in the Draft Red Herring Prospectus ('DRHP') in connection with its proposed initial public offering of equity shares of the Company in terms of the requirements of:

- Section 26 of Part I of Chapter III of the Companies Act, 2013, as amended ("the Act");
- The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (the "ICDR Regulations"); and
- The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note")



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

The Restated Consolidated Financial Information have been prepared by the management of the Company and compiled from:

1. Audited Special Purpose Interim Consolidated Ind AS Financial Statements of the Group as at and for the Period ended 30th September 2024 prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015, as amended and other accounting principles generally accepted in India which have been approved by the Board of Directors at their meetings held on 15.03.2025.
2. Audited Special Purpose Ind AS Financial Statements 2024-22 for the years March 31, 2024, March 31, 2023 and March 31, 2022 approved by the Board of Directors at their meetings held on 15.03.2025 being prepared by the management by making all the adjustments required under the Ind AS to the audited financial statements of the Company as at and for the years March 31, 2024, March 31, 2023 and March 31, 2022 which were prepared in accordance with the accounting standards notified under section 133 of the Act (" Indian GAAP") and other accounting principles generally accepted in India, at the relevant time, which have been approved by the respective Board of Directors at their meetings held on 27.08.2024, 25.09.2023 and 30.09.2022 respectively.

2.2 Basis of Consolidation

These consolidated financial statements include the financial statements of M/s GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED (the "Holding Company") and its subsidiary and entities under control (referred as Subsidiary Firms), prepared in accordance with Ind AS 110 – Consolidated Financial Statements. The financial statements of its subsidiary and entities under control (referred as Subsidiary Firms) have been combined on a line-by-line basis by adding together like items of assets, liabilities, income, and expenses.

Key principles of consolidation:

- **Intra-group balances, transactions, and unrealized profits/losses** arising from intra-group transactions are eliminated in full.
- **Non-controlling interests (NCI)**, where applicable, are presented separately within equity and profit/loss of the Group.
- **Uniform accounting policies** have been adopted for all entities included in consolidation.
- The financial statements of subsidiaries used in consolidation are drawn up to the **Same reporting date (30th September 2024)** as that of the Holding Company.

2.3 Compliance with Special Purpose Reporting

These consolidated financial statements are **Special purpose financial statements**, prepared exclusively for the purpose of **inclusion in the DRHP** to be filed with SEBI. They are **not intended for general-purpose financial reporting** or for statutory filing under the Companies Act, 2013.

These statements should be read along with the accompanying **summary of significant accounting policies and other explanatory notes**, which provide further details on the accounting policies, significant judgments, and estimates used in their preparation.

3 Summary of significant accounting policies

3.1 Property, plant and equipment:

Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, taxes, duties (including import duties), freight and any directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

Each part of an item of property, plant and equipment with a cost that is significant in relation to the total cost of the item is depreciated separately. This applies mainly to components for machinery. When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred.

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from its previously assessed standard of performance. All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Borrowing costs directly attributable to acquisition of property, plant and equipment which take substantial period of time to get ready for its intended use are also included to the extent they relate to the period till such assets are ready to be put to use.

Advances paid towards the acquisition of property, plant and equipment outstanding at each balance sheet date is classified as capital advances under other non-current assets.

An item of property, plant and equipment and any significant part initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the Property, plant and equipment is de-recognised.

Capital work-in-progress includes cost of Property, plant and equipment under installation / under development as at the balance sheet date less impairment losses, if any.

3.2 Depreciation on property, plant and equipment (PPE) :

Depreciation on property, plant and equipment is calculated on a written down method over the estimated useful lives of the assets prescribed in schedule II of the Companies Act 2013 or the Income Tax Act, 1961 (for the Subsidiary/Subsidiary Firms firms). However, in some cases, the management basis its past experience/technical assessment made by the independent valuation expert engaged by the Company, has estimated the useful lives, which is at variance with the life prescribed in Part C of Schedule II to the Act and has accordingly, depreciated the assets over such useful lives. The estimated useful lives, residual values and depreciation method are reviewed periodically, at least at each financial year-end, with the effect of any changes in estimate accounted for on a prospective basis.

3.3 Intangible assets and intangible assets under development :

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, they are carried at cost less accumulated amortisation and accumulated impairment losses, if any. Intangible assets with finite lives are amortised on a straight-line basis over their useful economic lives and assessed for impairment whenever there is an indication that their carrying amount may not be recovered. The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed periodically.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when asset is de-recognised.

Development costs incurred on internally generated intangible assets, not ready for use are capitalised as intangible assets under development.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

3.4 Borrowing Costs :

Borrowing cost includes interest, commitment charges, brokerage, underwriting costs, discounts / premiums, financing charges, exchange difference to the extent they are regarded as interest costs and all ancillary / incidental costs incurred in connection with the arrangement of borrowing. Borrowing costs which are directly attributable to acquisition / construction of qualifying assets that necessarily takes a substantial period of time to get ready for its intended use are capitalised as a part of cost pertaining to those assets. All other borrowing costs are recognised as expense in the period in which they are incurred. The capitalisation of borrowing costs commences when the Company incurs expenditure for the asset, incurs borrowing cost and undertakes activities that are necessary to prepare the asset for its intended use or sale. The capitalisation of borrowing costs is suspended during extended periods in which active development of a qualifying asset is suspended. The capitalisation of borrowing costs ceases when substantially all the activities necessary to prepare the qualifying asset for its intended use.

3.5 Impairment of Property, plant and equipment :

At the end of each reporting period, the Company reviews the carrying amounts of its PPE and other intangible assets to determine whether there is any indication that these assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit (CGU) to which the asset belongs. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. The resulting impairment loss is recognised in the Statement of Profit and Loss.

The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

Where an impairment loss subsequently reverses, the carrying amount of the asset or CGU is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset or CGU in prior years. A reversal of an impairment loss is recognised in the Statement of Profit and Loss.

3.6 Inventories:

Inventories of drugs, consumables, surgical items, and stores & spares are valued at lower of cost and net realisable value. Cost includes the cost of purchase, duties, taxes (other than those recoverable from tax authorities) and other cost incurred in bringing the inventories to their present location and condition. Cost is determined on first-in first-out ("FIFO") basis. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

3.7 Revenue recognition:

The Company earns revenue primarily by providing healthcare services, sale of drugs and medical consumables. Other sources of revenue include medical service agreements, clinical trials, sponsorship etc.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

a) Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Revenue is measured based on the transaction price, which is the consideration, adjusted for discounts and other credits, if any, as specified in the contract with the customer. Goods and services tax is not received by the Company on its own account. Rather, it is tax collected by the seller on behalf of the government. Revenue is usually recognised when it is probable that economic benefits associated with the transaction will flow to the entity, amount of revenue can be measured reliably and entity retained neither ownership nor effective control over the goods sold or services rendered.

b) Revenue from healthcare services

The Healthcare services income include revenue generated from outpatients, which mainly consist of activities for physical examinations, treatments, surgeries and tests, as well as that generated from inpatients, which mainly consist of activities for clinical examinations and treatments, surgeries, and other fees such as room charges, and nursing care. The performance obligations for this stream of revenue include food & beverage, accommodation, surgery, medical/clinical professional services, supply of equipment, investigation and supply of pharmaceutical and related products.

The patient is obligated to pay for healthcare services at amounts estimated to be receivable based upon the Company's standard rates or at rates determined under reimbursement arrangements. The reimbursement arrangements are generally with third party administrators. The reimbursement is also made through national, international or local government programs with reimbursement rates established by statute or regulation or through a memorandum of understanding.

Revenue is recognized as follows:

At a point in time: Revenue from pharmacy sales, consultation fees, and one-time medical procedures is recognized when the customer obtains control of the service or product.

Over time: Revenue from long-term healthcare plans, inpatient hospital services, and clinical trials is recognized as the services are rendered.

c) Revenue from sale of pharmaceutical products

Revenue from sale of pharmacy goods is recognised at a point in time when control of the goods is transferred to the customer, and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection. The amount of revenue recognised is net of sales returns, taxes and duties, wherever applicable.

d) Other Services rendered

Income from other services like sponsorship income, education income, clinical trials and other ancillary activities is recognised based on the terms of the contract and when it is probable that economic benefits associated with the transaction will flow to the entity and amount of revenue can be measured reliably.

e) Other Income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a timely basis, by reference to the principal outstanding and at the effective interest rate applicable. Dividend income is recognised when the Company's right to receive dividend is established by the reporting date. Dividend income is included under the head "other income" in the statement of profit and loss.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

3.8 Government Grant

Government grants are recognised where there is reasonable assurance that the grant will be received and all the conditions attached with them will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in proportion to the fulfilment of its obligations under such Government grant.

3.9 Employee Benefits

a) Short term employee benefits

Employee benefits payable wholly within twelve months of receiving services are classified as short-term employee benefits. These benefits include salary and wages, bonus and exgratia. The undiscounted amount of short-term employee benefits to be paid in exchange for employee services is recognised as an expense as the related service is rendered by the employees.

b) Post-Employment Benefits

The Company provides the following post employment benefits:

- (i) Defined benefit plans such as gratuity; and
- (ii) Defined contributions plan such as provident fund.

bi) Defined contribution plans - Provident fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The Company makes specified obligations towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's contributions are recognised as an expense in the statement of profit and loss during the period in which the employee renders the related service.

bii) Defined benefit plans - Gratuity obligations

The liability or asset recognised in the balance sheet in respect of defined benefit pension and gratuity plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by actuaries using the projected unit credit method.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss.


Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income.

3.10 Taxes on Income:

Tax expense comprises deferred tax and current tax expenses. Income tax expense is recognised in statement of profit and loss except to the extent that it relates to equity, in which case it is recognised in equity or other comprehensive income.

a) Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income Tax Act, 1961 and the Income Computation and Disclosure Standards ("ICDS") enacted in India by using tax rates and tax laws that are enacted or substantively enacted, at the reporting date.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

Current income tax relating to items recognised outside profit or loss is included either in other comprehensive income or in equity depending on the recognition of underlying transaction. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

b) Deferred tax

Deferred income tax is recognised using the balance sheet approach, deferred tax is recognised on temporary differences at the balance sheet date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.

Deferred income tax assets are recognised for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

3.11 Earnings Per Share:

Basic earnings/ (loss) per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings/ (loss) per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

3.12 Cash & Cash Equivalents and cash flows

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

a) Cash and cash equivalents:

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

3.13 Provisions

A provision is recognised when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of such obligation. Provisions are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably. The expense relating to any provision is presented in the statement of profit and loss net of any reimbursement.

3.14 Contingent liabilities

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events but is not recognised because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognise a contingent liability but discloses it in the financial statements, unless the possibility of an outflow of resources embodying economic benefits is remote.

3.15 Foreign currency translation

The financial statements of Company are presented in Indian Rupees, which is also the functional currency. In preparing the financial statements, transactions in currencies other than the entity's functional currency are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at that date. Non-monetary items denominated in foreign currency are reported at the exchange rate ruling on the date of transaction.

Exchange differences on monetary items are recognised in the statement of profit and loss in the period in which they arise except for exchange differences on foreign currency borrowings relating to assets under construction for future productive use, which are included in the cost of those assets when they are regarded as an adjustment to interest costs on those foreign currency borrowings.

3.16 Segment Reporting

In accordance with Ind AS 108, Segment Reporting, the Chief Executive Officer and Managing Director is the Company's Chief Operating Decision Maker ("CODM"). The Company's business activity primarily falls within a single reportable business segment and geographical segment namely 'Medical and Healthcare Services' and 'India' respectively. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements.

3.17 Current and Non-current Classification:

The Company presents assets and liabilities in the Balance Sheet based on current/ non-current classification.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

- a) **An asset is current when it is:**
- Expected to be realised or intended to be sold or consumed in the normal operating cycle,
 - Held primarily for the purpose of trading,
 - Expected to be realised within twelve months after the reporting period, or
 - Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.
- All other assets are classified as non-current.
- b) **A liability is current when:**
- It is expected to be settled in the normal operating cycle,
 - It is held primarily for the purpose of trading,
 - It is due to be settled within twelve months after the reporting period, or
 - There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.
- All other liabilities are classified as non-current.
- c) **The Operating Cycle and Classification of Current and Non-Current Assets and Liabilities**
- The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has evaluated and considered its operating cycle as one year and accordingly has reclassified its assets and liabilities into current and non-current.

3.18 Dividend

A final dividend, including tax thereon, on equity shares is recorded as a liability on the date of approval by the shareholders. An interim dividend, including tax thereon, is recorded as a liability on the date of declaration by the board of directors.

3.19 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. The Company recognises a financial asset or financial liability in its balance sheet only when the entity becomes party to the contractual provisions of the instrument.

a) **Financial assets:**

A financial asset inter-alia includes any asset that is cash, equity instrument of another entity or contractual obligation to receive cash or another financial asset or to exchange financial asset or financial liability under condition that are potentially favourable to the Company.

Initial recognition and measurement

Financial assets are initially measured at fair value except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets (other than financial assets at fair value through profit or loss) are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at fair value through profit or loss are recognised immediately in statement profit or loss.

Subsequent measurement

For purposes of subsequent measurement financial assets are classified in three categories:

- i) Financial assets measured at amortised cost
- ii) Financial assets at fair value through OCI
- iii) Financial assets at fair value through Statement of Profit and Loss



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

Measured at amortized cost:

Financial assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows that are solely payments of principal and interest, are subsequently measured at amortized cost using the effective interest rate ('EIR') method less impairment, if any, the amortization of EIR and loss arising from impairment, if any is recognized in the Statement of Profit and Loss.

Derecognition:

The Company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

Impairment:

In accordance with Ind AS 109, the Company applies expected credit losses ("ECL") model for measurement and recognition of impairment loss on the following financial asset and credit risk exposure.

- i) Financial assets measured at amortised cost
- ii) Financial assets measured at fair value through other comprehensive income (FVTOCI);

The Company follows "simplified approach" for recognition of impairment loss allowance on trade receivables. Under the simplified approach, the Company does not track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at the time of initial revenue recognition. The Company uses a provision matrix to determine impairment loss allowance on the portfolio of trade receivables. The provision matrix is based on the historically observed default rates over the expected life of various categories of trade receivables and these are updated and changed based on forward looking estimates at every reporting date.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the Company reverts to recognizing impairment loss allowance based on 12 months ECL.

b) Financial liabilities

Financial liabilities include loans and borrowings including bank overdraft, trade payable, accrued expenses and other payables.

Initial recognition and measurement

All financial liabilities at initial recognition are classified as financial liabilities at amortised cost or financial liabilities at fair value through profit or loss, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Subsequent measurement

The subsequent measurement of financial liabilities depends upon the classification as described below:

Financial liabilities classified as amortised cost: -

Financial liabilities that are not held for trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent accounting periods. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the Effective Interest Rate. Interest expense that is not capitalised as part of costs of assets is included as finance costs in the Statement of Profit and Loss.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

Financial liabilities at fair value through profit and loss (FVTPL): -

FVTPL includes financial liabilities held for trading and financial liabilities designated upon initial recognition as FVTPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. Financial liabilities have not been designated upon initial recognition at FVTPL.

De-recognition.

A financial liability is derecognised when the obligation under the liability is discharged / cancelled / expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

Offsetting financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

3.20 Leases

a) Company as a lessee:

The company recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, company's incremental borrowing rate. Generally, the company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- Fixed payments, including in-substance fixed payments;
- Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable under a residual value guarantee; and
- The exercise price under a purchase option that the company is reasonably certain to exercise, lease payments in an optional renewal period if the company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the company is reasonably certain not to terminate early.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the company's estimate of the amount expected to be payable under a residual value guarantee, or if company changes its assessment of whether it will exercise a purchase, extension or termination option.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

b) Short-term leases and leases of low-value assets Company as a lessee:

The company has elected not to recognise right-of-use assets and lease liabilities for short term leases of real estate properties that have a lease term of 12 months. The company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

c) Company as a lessor:

Lease income from operating leases where the Company is a lessor is recognised in income on a straight-line basis over the lease term unless the receipts are structured to increase in line with expected general inflation to compensate for the expected inflationary cost increases. The respective leased assets are included in the balance sheet based on their nature.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the company to the lessee. Amounts due from lessees under finance leases are recorded as receivables. Finance lease income is allocated to accounting periods to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

3.21 Fair Value Measurement:

The Company measures financial instruments of certain investments at fair value, at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

For assets and liabilities that are recognised in the balance sheet on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

3.22 Functional and presentation currency

Items included in the Ind AS Financial Statements of the Company is measured using the currency of the primary economic environment in which the Company operates (i.e., the functional currency"). The IndAS Financial Statements is presented in Indian Rupee, which is the functional as well as presentation currency of the Company.

All amounts in these IndAS Financial Statements and notes have been presented in INR Lakhs rounded to two decimals as per the requirements of Schedule III of the Companies Act, 2013, unless otherwise stated. Transactions and balances with values below the rounding off norm adopted by the Company have been reflected as "0" in the relevant notes to this IndAS Financial Statements.

3.23 Security Deposit

Under Ind AS 109 - Financial Instruments, a refundable security deposit is considered a financial instrument, and if the deposit is expected to be refunded at a future date, it must be initially recognized at its present value.

- **Present Value Calculation:**

The deposit is discounted using a rate that reflects the time value of money. If the deposit is refunded after several years, this could result in a significant difference between the nominal value of the deposit and its present value. The discount rate used is typically the market rate for similar instruments, which reflects the credit risk and the time value of money.

- **Initial Recognition at Present Value:**

At the inception of the agreement, the refundable deposit is recognized at its present value. The difference between the nominal amount and the present value is typically recognized as interest income over time (using the effective interest rate method) in the profit and loss account.

3.24 Business Combinations

The Company accounts for business combinations using the acquisition method, recognizing identifiable assets acquired, liabilities assumed, and any non-controlling interest at their fair values on the acquisition date. Consideration transferred includes cash, equity instruments issued, contingent consideration, and fair value of previously held interests, if any. Goodwill is recognized when the purchase consideration exceeds the net fair value of assets acquired, while a bargain purchase gain is recognized in profit or loss if the net assets exceed the purchase consideration, after reassessment. Transaction costs incurred in a business combination are expensed as incurred. Contingent consideration is measured at fair value on the acquisition date, with subsequent changes recognized in profit or loss unless classified as equity.

4 Significant accounting judgements, estimates and assumptions

The preparation of the Company's Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

4.1 Use of Estimates

The preparation of Financial Statements in conformity with Ind AS requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a adjustment to the carrying amount of the asset or liability affected in future periods.

The key judgment, estimates and assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next year, are described below. The Company based its judgments and assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

4.2 Key Judgements

Significant accounting judgements, estimates and assumptions used by management are as below:

i) Revenue from Operations

Revenue primarily comprises fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used in treatments given to patients. Revenue from hospital services are recognised as and when services are performed, unless significant future uncertainties exist. The Company assess the distinct performance obligation in the contract and measures to at an amount that reflects the consideration it expects to receive net of tax collected and remitted to Government and adjusted for discounts and concession. The Company based on contractual terms and past experience determines the performance obligation satisfaction over time.

ii) Defined Benefit schemes

The cost of the defined benefit plan and the present value of the defined benefit obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate; future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds. The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases are based on expected future inflation rates and expected salary increase thereon.

iii) Useful lives of property, plant and equipment

The useful life and residual value of property, plant and equipment and intangible assets are determined based on evaluation made by the management of the expected usage of the asset, the physical wear and tear and technical or commercial obsolescence of the asset. Due to the judgments involved in such estimates the useful life and residual value are sensitive to the actual usage in future period.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

iv) Assessment of claims and litigations disclosed as contingent liabilities

There are certain claims and litigations which have been assessed as contingent liabilities by the management and which may have an effect on the operations of the Company. The management has assessed that no further provision / adjustment is required to be made in the financial statements for the above matters, other than what has been already recorded, as they expect a favourable decision based on their assessment and the advice given by the external legal counsels / professional advisors.

v) Deferred Tax

Deferred income tax reflects the current period timing differences between taxable income and accounting income for the period and reversal of timing differences of earlier periods. Deferred tax assets & liabilities are measured using the tax rates and tax law that have been enacted by the Income-tax Act as at the balance sheet date. Provision for Deferred Tax Liability is made to take care of timing difference in tax treatment of various expenses but mainly of depreciation.

5 New and amended standards

Amendments to Ind AS 1 and Ind AS 8: Definition of Material The amendments provide a new definition of material that states, "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The amendments clarify that materiality will depend on the nature or magnitude of information, either individually or in combination with other information, in the context of the financial statements. A misstatement of information is material if it could reasonably be expected to influence decisions made by the primary users. These amendments had no impact on the financial statements of, nor is there expected to be any future impact to the Company. These amendments are applicable prospectively for annual periods beginning on or after the 1st April, 2020. The amendments to the definition of material are not expected to have a significant impact on the financial information.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

6. Property, Plant and Equipment

Name of Assets	Gross Block					Depreciation and Amortization					Net Block
	As on 01 April 2024	Acquisition through business combination	Addition	Deduction	As on 30 September 2024	As on 01 April 2024	Acquisition through business combination	Addition	Deduction	As on 30 September 2024	As on 30 September 2024
(i) Property, Plant and Equipment											
Plant and Equipment	718.50	213.52	49.33	-	981.35	19.14	104.82	87.13	-	211.09	770.26
Building	122.33	22.29	-	-	144.62	0.61	6.85	2.99	-	10.45	134.16
Furniture and Fixtures	114.72	26.87	0.36	-	141.95	6.50	10.66	30.32	-	47.48	94.47
Vehicles	12.18	55.90	-	-	68.07	0.74	33.07	3.48	-	37.29	30.78
Office equipment	32.81	13.90	-	-	46.71	0.95	7.33	4.94	-	13.22	33.49
Computers	1.55	4.49	0.87	-	6.93	0.31	3.20	0.46	-	3.97	2.96
Total	1,002.09	336.97	50.56	-	1,389.63	28.25	165.93	129.32	-	323.50	1,066.12

Name of Assets	Gross Block					Depreciation and Amortization					Net Block
	As on 01 April 2023	Acquisition through business combination	Addition	Deduction	As on 31 March 2024	As on 01 April 2023	Acquisition through business combination	Addition	Deduction	As on 31 March 2024	As on 31 March 2024
(i) Property, Plant and Equipment											
Plant and Equipment	-		718.50	-	718.50	-		19.14	-	19.14	699.36
Building	-		122.33	-	122.33	-		0.61	-	0.61	121.72
Furniture and Fixtures	-		114.72	-	114.72	-		6.50	-	6.50	108.22
Vehicles	-		12.18	-	12.18	-		0.74	-	0.74	11.44
Office equipment	-		32.81	-	32.81	-		0.95	-	0.95	31.86
Computers	-		1.55	-	1.55	-		0.31	-	0.31	1.24
Total			1,002.09	-	1,002.09	-		28.25	-	28.25	973.84



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

6. Property, Plant and Equipment

Name of Assets	Gross Block					Depreciation and Amortization					Net Block
	As on 01 April 2022	Acquisition through business combination	Addition	Deduction	As on 31 March 2023	As on 01 April 2022	Acquisition through business combination	Addition	Deduction	As on 31 March 2023	As on 31 March 2023
(i) Property, Plant and Equipment											
Plant and Equipment	324.58		-	324.58	-	57.40		-	57.40	-	-
Total	324.58		-	324.58	-	57.40		-	57.40	-	-

Name of Assets	Gross Block					Depreciation and Amortization					Net Block
	As on 01 April 2021	Acquisition through business combination	Addition	Deduction	As on 31 March 2022	As on 01 April 2021	Acquisition through business combination	Addition	Deduction	As on 31 March 2022	As on 31 March 2022
(i) Property, Plant and Equipment											
Plant and Equipment	324.58		-	-	324.58	-		57.40	-	57.40	267.18
Total	324.58		-	-	324.58	-		57.40	-	57.40	267.18



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

7 Right of Use Assets**As at 30 September 2024**

Particulars	Land & Building	Plant & Machinery	Others	Total
Cost as at 01 April 2024	393.90	-	-	393.90
Addition	-	-	-	-
Disposals	-	-	-	-
Acquisition through business combination	193.57	-	-	193.57
Cost as at 30 September 2024	587.47	-	-	587.47
Accumulated amortisation as at 01 April 2024	3.68	-	-	3.68
Acquisition through business combination	91.44	-	-	91.44
Amortization charge for the year	22.07	-	-	22.07
Reversal on Disposal of assets	-	-	-	-
Accumulated amortisation as at 30 September 2024	117.19	-	-	117.19
Net Carrying Amount as at 30 September 2024	470.28	-	-	470.28

Right of Use Assets**As at 31 March 2024**

Particulars	Land & Building	Plant & Machinery	Others	Total
Cost as at 01 April 2023	-	-	-	-
Addition	393.90	-	-	393.90
Disposals	-	-	-	-
Cost as at 31 March 2024	393.90	-	-	393.90
Accumulated amortisation as at 01 April 2023	-	-	-	-
Amortization charge for the year	3.68	-	-	3.68
Reversal on Disposal of assets	-	-	-	-
Accumulated amortisation as at 31 March 2024	3.68	-	-	3.68
Net Carrying Amount as at 31 March 2024	390.22	-	-	390.22

Right of Use Assets**As at 31 March 2023**

Particulars	Land & Building	Plant & Machinery	Others	Total
Cost as at 01 April 2022	-	-	-	-
Addition	-	-	-	-
Disposals	-	-	-	-
Cost as at 31 March 2023	-	-	-	-
Accumulated amortisation as at 01 April 2022	-	-	-	-
Amortization charge for the year	-	-	-	-
Reversal on Disposal of assets	-	-	-	-
Accumulated amortisation as at 31 March 2023	-	-	-	-
Net Carrying Amount as at 31 March 2023	-	-	-	-

Right of Use Assets**As at 31 March 2022**

Particulars	Land & Building	Plant & Machinery	Others	Total
Cost as at 01 April 2021	-	-	-	-
Addition	-	-	-	-
Disposals	-	-	-	-
Cost as at 31 March 2022	-	-	-	-
Accumulated amortisation as at 01 April 2021	-	-	-	-
Amortization charge for the year	-	-	-	-
Reversal on Disposal of assets	-	-	-	-
Accumulated amortisation as at 31 March 2022	-	-	-	-
Net Carrying Amount as at 31 March 2022	-	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Goodwill				
Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Opening Balance	-	-	-	-
Add: Addition during the year	-	-	-	-
Less: Deletion during the year	-	-	-	-
Closing Balance	-	-	-	-

Particulars of business combinations accounted by the group

Particulars	Acquisition Year	Consideration Paid	Total Assets	Total Liabilities	Net Assets Acquired	Non Controlling Interest	Goodwill / (Gain on Bargain Purchase)
Gujarat Kidney and Superspeciality Hospital	2023-24	906.37	1,364.96	458.60	906.37	-	-
Gujarat Surgical Hospital	2024-25	9.00	93.62	83.62	10.00	1.00	-
Surya Hospital and ICU	2024-25	17.83	130.09	110.28	19.81	1.98	-
Raj Palmland Hospital Pvt Ltd	2024-25	124.62	718.38	429.60	288.78	141.50	-22.66
Total		1,057.82	2,307.05	1,082.10	1,224.96	144.48	-22.66

The group accounts for business combinations using the acquisition method of accounting. This method requires the application of fair values for both the consideration given and the assets and liabilities acquired.

During the Period, the Group had the business combinations primarily comprising acquisition of "Gujarat Kidney and Superspeciality Hospital (Proprietorship of Pragnesh Bharpoda)" "Gujarat Surgical Hospital", "Surya Hospital and ICU", Raj Palmland Pvt Ltd" on a going concern basis. As part of the acquisition, the Group acquired the assets, liabilities, employees etc. as determined pursuant to the acquisition agreements and also continuity of the acquiree Doctors who are also covered by a non-compete and have entered into a service contract to provide services to the Group.

There are non-controlling interests in the business combinations entered during the year. The details of the eligible/identifiable assets and liabilities have been furnished above. The resultant goodwill/gain on bargain purchase on such business combinations consists primarily of the synergies, increase in market share, workforce etc. The amount of such goodwill is not expected to be deductible for tax purposes.

8 Capital Work in progress

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Opening Balance	-	-	-	-
Add: Addition during the year	23.38	-	-	-
Less: Capitalised during the year	-	-	-	-
Closing Balance	23.38	-	-	-

8.1 Capital Work-in-Progress Ageing Schedule**As at 30 September 2024**

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 -2 Years	2-3 Years	More than 3 Years	
Projects in progress	23.38	-	-	-	23.38
Projects temporarily suspended	-	-	-	-	-

9 Other financial assets - non current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Security deposits	15.00	5.62	-	-
Bank deposits with more than 12 months maturity	19.49	-	-	-
Total	34.49	5.62	-	-

10 Deferred tax assets, net

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Deferred tax assets, net	33.32	2.64	4.19	4.18
Deferred tax assets, net				
Total	33.32	2.64	4.19	4.18



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Deferred Tax Assets/Liability

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Deferred Tax Assets				
Depreciation	22.26	2.05	4.04	4.04
Other timing difference	0.07	0.11	0.15	0.15
Lease Liability	5.81	0.48	-	-
Gratuity	6.08	-	-	-
Total DTA	34.22	2.64	4.19	4.19
B				
Remeasurement	0.90	-	-	-
Total DTL	0.90	-	-	-
Deferred Tax Assets, net	33.32	2.64	4.19	4.19

Movement in deferred tax assets/liability**As at 30 September 2024**

Particulars	Opening balance	Acquisition through business combination	Recognised to P&L	Recognised to OCI	Closing balance
A.					
Depreciation	2.05	6.20	14.01		22.26
Other timing difference	0.11	-	-0.04		0.07
Lease Liability	0.48	2.52	2.81		5.81
Gratuity		4.33	1.75		6.08
Total DTA	2.64	13.05	18.53	-	34.22
B					
Remeasurement				0.90	0.90
Total DTL	-	-	-	0.90	0.90
Net	2.64	13.05	18.53	-0.90	33.32

Movement in deferred tax assets/liability**As at 31 March 2024**

Particulars	Opening balance	Acquisition through business combination	Recognised to P&L	Recognised to OCI	Closing balance
A.					
Depreciation	4.04	-	-1.99		2.05
Other timing difference	0.15	-	-0.04		0.11
Lease Liability		-	0.48		0.48
Gratuity		-			
Total DTA	4.19	-	-1.55	-	2.64
B					
Total DTL	-	-	-	-	-
Net	4.19	-	-1.55	-	2.64

Movement in deferred tax assets/liability**As at 31 March 2023**

Particulars	Opening balance	Acquisition through business combination	Recognised to P&L	Recognised to OCI	Closing balance
A.					
Depreciation	4.04	-			4.04
Other timing difference	0.15	-			0.15
Total DTA	4.19	-	-	-	4.19
B					
Total DTL	-	-	-	-	-
Net	4.19	-	-	-	4.19



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

Movement in deferred tax assets/liability

As at 31 March 2022

Particulars	Opening balance	Acquisition through business combination	Recognised to P&L	Recognised to OCI	Closing balance
A.		-			
Depreciation	2.17	-	1.87		4.04
Other timing difference	0.20	-	-0.05		0.15
Total DTA	2.37	-	1.82	-	4.19
B	-	-	-	-	-
Total DTL	-	-	-	-	-
Net	2.37	-	1.82	-	4.19

11 Other non current assets

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Prepaid expenses	9.90	7.35	-	-
Assets Held for Sale	-	-	267.18	-
Total	9.90	7.35	267.18	-

12 Inventories

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Medical consumables, drugs and surgical items	37.61	27.00	-	-
Total	37.61	27.00	-	-

13 Trade receivables - current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Unsecured, considered good	1,204.71	420.17	115.00	116.07
Total	1,204.71	420.17	115.00	116.07

Trade Receivables Ageing schedule

As at 30 September 2024

Particulars	Undue	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables							
-considered good	-	899.40	190.13	50.26	22.56	42.36	1,204.71
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables							
-considered good	-	-	-	-	-	-	-
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Sub Total	-	899.40	190.13	50.26	22.56	42.36	1,204.71
Unbilled - considered good							-
Unbilled - which have significant increase in credit risk							-
Unbilled - credit impaired							-
Provision for doubtful debts							-
Total							1,204.71



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Trade Receivables Ageing schedule**As at 31 March 2024**

Particulars	Undue	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables							
-considered good	-	420.17	-	-	-	-	420.17
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables							
-considered good	-	-	-	-	-	-	-
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Sub Total	-	420.17	-	-	-	-	420.17
Unbilled - considered good							-
Unbilled - which have significant increase in credit risk							-
Unbilled - credit impaired							-
Provision for doubtful debts							-
Total							420.17

Trade Receivables Ageing schedule**As at 31 March 2023**

Particulars	Undue	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables							
-considered good	-	-	-	78.60	36.40	-	115.00
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables							
-considered good	-	-	-	-	-	-	-
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Sub Total	-	-	-	78.60	36.40	-	115.00
Unbilled - considered good							-
Unbilled - which have significant increase in credit risk							-
Unbilled - credit impaired							-
Provision for doubtful debts							-
Total							115.00

Trade Receivables Ageing schedule**As at 31 March 2022**

Particulars	Undue	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables							
-considered good	-	26.76	51.85	37.46	-	-	116.07
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables							
-considered good	-	-	-	-	-	-	-
-which have significant	-	-	-	-	-	-	-
-credit impaired	-	-	-	-	-	-	-
Sub Total	-	26.76	51.85	37.46	-	-	116.07
Unbilled - considered good							-
Unbilled - which have significant increase in credit risk							-
Unbilled - credit impaired							-
Provision for doubtful debts							-
Total							116.07



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

14 Cash and cash equivalents

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Balances with Banks	372.18	78.14	0.35	0.34
Cash on hand	50.36	18.90	-	-
Total	422.54	97.04	0.35	0.34

15 Bank balances other than Cash and cash equivalents

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Bank deposits with original maturity of 3-12 months	240.68	20.46	-	-
Total	240.68	20.46	-	-

16 Other financial assets - current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Security deposits	0.15	-	-	-
Interest accrued on bank deposit	4.66	0.19	-	-
Total	4.81	0.19	-	-

17 Other current assets

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Advances other than capital advances	0.52	-	-	-
Advances to suppliers	17.93	5.30	-	-
Prepaid expenses	32.28	29.64	-	-
Advances to employees	9.51	-	-	-
Business transfer collectibles	-	60.26	-	-
Capital advances	17.48	12.83	-	-
Current Tax Assets, net - Subsidiary/Subsidiary Firms	39.04	-	-	-
Total	116.76	108.03	-	-

18 Equity Share Capital

Particulars	As at 30 September 2024	As at 31 March 2024
Authorised Share Capital		
190000000 (PY - 190000000) Equity Shares of Rs. 2 each	3,800.00	3,800.00
Issued, subscribed & fully paid up		
1609550 (PY - 1000000) Equity Shares of Rs. 2 each	32.19	20.00
Total	32.19	20.00

Reconciliation of Share Capital

Particulars	As at 30 September 2024		As at 31 March 2024	
	Number of Shares	Amount	Number of Shares	Amount
Opening Balance	10,00,000	20.00	10,00,000	20.00
Changes due to prior period error	-	-	-	-
Issued during the year	6,09,550	12.19	-	-
Adjustment	-	-	-	-
Deletion	-	-	-	-
Closing balance	16,09,550	32.19	10,00,000	20.00



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Note:

1) During the year, the Company allotted 1,16,950 equity shares of ₹10 each at an issue price of ₹775 per share (including a securities premium of ₹765 per share) to Mr. Pragnesh Bharpoda, a director of the Company, as consideration for the acquisition of business assets and liabilities under a Business Transfer Agreement (BTA) dated 18.02.2024. The total value of shares issued as consideration was ₹9,06,36,351, based on valuation report of registered valuer, representing the net asset value of the acquired business.

2) Pursuant to the resolution passed by the Board of Directors and approved by the shareholders of the Company, the equity shares of the Company having a face value of ₹10 each were sub-divided into equity shares of ₹2 each. Accordingly, 3,16,950 equity shares of ₹10 each have been split into 1,584,750 equity shares of ₹2 each, effective from 22.07.2024.

3) Pursuant to the resolution passed by the Board of Directors and approved by the shareholders of the Company, the Company has issued 24,800 equity shares of face value ₹2 each on a rights basis at an issue price of ₹1000 per share (including a premium of ₹998 per share). The rights issue was undertaken in compliance with applicable laws and regulations, and the shares were allotted on 29.09.2024.

Equity Share Capital

Particulars	As at 31 March 2023	As at 31 March 2022
Authorised Share Capital		
1250000 (PY - 1250000) Equity Shares of Rs. 2 each	25.00	25.00
Issued, subscribed & fully paid up		
1000000 (PY - 1000000) Equity Shares of Rs. 2 each	20.00	20.00
Total	20.00	20.00

Reconciliation of Share Capital

Particulars	As at 31 March 2023		As at 31 March 2022	
	Number of Shares	Amount	Number of Shares	Amount
Opening Balance	10,00,000	20.00	10,00,000	20.00
Changes due to prior period error	-	-	-	-
Issued during the year	-	-	-	-
Adjustment	-	-	-	-
Deletion	-	-	-	-
Closing balance	10,00,000	20.00	10,00,000	20.00

Rights, preferences and restrictions attached to shares

Equity Shares: The Company has one class of equity shares. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Equity Share holder holding more than 5%

Name of Share Holder	As at 30 September 2024		As at 31 March 2024	
	No of Shares	% of Shareholding	No of Shares	% of Shareholding
Anitaben Bharpoda	2,50,000.00	0.16	2,50,000.00	0.25
Bhartiben Bharpoda	2,49,985.00	0.16	2,49,985.00	0.25
Pragnesh Bharpoda	8,59,550.00	0.53	2,50,000.00	0.25
Yashwantsingh Bharpoda	2,50,000.00	0.16	2,50,000.00	0.25

Equity Share holder holding more than 5%

Name of Share Holder	As at 31 March 2023		As at 31 March 2022	
	No of Shares	% of Shareholding	No of Shares	% of Shareholding
Anitaben Bharpoda	2,50,000.00	0.25	2,50,000.00	0.25
Bhartiben Bharpoda	2,50,000.00	0.25	2,50,000.00	0.25
Pragnesh Bharpoda	2,50,000.00	0.25	2,50,000.00	0.25
Yashwantsingh Bharpoda	2,50,000.00	0.25	2,50,000.00	0.25



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

Shares held by promoters

As at 30 September 2024

Name of Promotor	Class of Shares Equity/Preference	No. of Shares	% of total shares	% Change during the year
Anitaben Bharpoda	Equity	2,50,000.00	0.16	-0.10
Bhartiben Bharpoda	Equity	2,49,985.00	0.16	-0.09
Pragnesh Bharpoda	Equity	8,59,550.00	0.53	0.28
Yashwantsingh Bharpoda	Equity	2,50,000.00	0.16	-0.09

As at 31 March 2024

Name of Promotor	Class of Shares Equity/Preference	No. of Shares	% of total shares	% Change during the year
Anitaben Bharpoda	Equity	2,50,000.00	0.25	-
Bhartiben Bharpoda	Equity	2,49,985.00	0.25	-
Pragnesh Bharpoda	Equity	2,50,000.00	0.25	-
Yashwantsingh Bharpoda	Equity	2,50,000.00	0.25	-

As at 31 March 2023

Name of Promotor	Class of Shares Equity/Preference	No. of Shares	% of total shares	% Change during the year
Anitaben Bharpoda	Equity	2,50,000.00	0.25	-
Bhartiben Bharpoda	Equity	2,50,000.00	0.25	-
Pragnesh Bharpoda	Equity	2,50,000.00	0.25	-
Yashwantsingh Bharpoda	Equity	2,50,000.00	0.25	-

As at 31 March 2022

Name of Promotor	Class of Shares Equity/Preference	No. of Shares	% of total shares	% Change during the year
Anitaben Bharpoda	Equity	2,50,000.00	0.25	-
Bhartiben Bharpoda	Equity	2,50,000.00	0.25	-
Pragnesh Bharpoda	Equity	2,50,000.00	0.25	-
Yashwantsingh Bharpoda	Equity	2,50,000.00	0.25	-

19 Other Equity

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Share application pending allotment	-	906.37	-	-
Capital Reserve	22.66	-	-	-
Securities premium	1,142.18	-	-	-
Retained earnings	717.18	154.06	17.02	17.65
Other items of OCI	2.69	-	-	-
Total	1,884.71	1,060.43	17.02	17.65



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Movement of Other Equity

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Share application pending allotment				
Opening Balance	906.37	-		
Add: Application money received		906.37		
Allotment of Equity Shares	-906.37			
Closing Balance	-	906.37		
Capital Reserve				
Opening Balance	-	-		
Add: Transfer from P&L	-	-		
Less: Deletion				
Transferred from OCI - Gain on Bargain Purchase	22.66			
Closing Balance	22.66	-		
Securities premium				
Opening Balance	-	-		
Add: Issue of Equity Shares	1,142.18			
Less: Deletion				
Closing Balance	1,142.18	-		
Retained Earnings				
Balance at the beginning of the year	154.05	17.02	17.65	7.65
Add: Profit/(Loss) during the year	563.13	171.40	-0.62	10.00
Expense for increase of authorised capital		-34.36		
Balance at the end of the year	717.18	154.06	17.02	17.65
Other items of OCI				
Opening Balance	-	-	-	-
Remeasurement Gain/(Loss) of defined Benefit Plan	2.69		-	-
Gain on Bargain Purchase	22.66			
Transferred to Capital Reserve - Gain on Bargain Purchase	-22.66			
Closing Balance	2.69	-	-	-
Total	1,884.71	1,060.43	17.02	17.65

Nature of Reserve & Surplus**Share application pending allotment**

share application money pending allotment is essentially an advance paid by potential shareholders, held by the company until the process of share allotment is completed. Once shares are allotted, the money is transferred to the company's equity as part of the share capital.

Retained Earnings

Retained earnings are the profits that the Company has earned till date, less any transfer to general reserves & dividend.

Securities premium

This reserve represents the amount received in excess of the face value of equity shares and is utilized in accordance with the provisions of the Companies Act, 2013. It is not available for distribution as dividends.

Capital Reserve

This reserve arises from specific capital transactions such as gain on bargain purchase of an acquisition on consolidation and is not available for distribution as dividends. It is maintained to strengthen the financial position of the Company.

Other items of OCI

This reserve comprises unrealized gains or losses recognized in other comprehensive income, including fair value adjustments. These amounts are not reclassified to profit or loss.

20 Non controlling interests

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Gujarat Surgical	1.00	-	-	-
Raj Palmland	141.50	-	-	-
Surya Hospital	1.98	-	-	-
Total	144.48	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

20.1 Non controlling interests (NCI)

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Balance on acquisition date	144.48	-	-	-
Balance at beginning of the year	-	-	-	-
Profit/(loss) attributable to NCI	-	-	-	-
Dividend paid by Subsidiary/Subsidiary Firms to NCI	-	-	-	-
Remeasurements of the defined benefit plans	-	-	-	-
Balance at end of the period	144.48	-	-	-

21 Borrowings - non current financial liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Secured Term loans from Bank	140.61	153.03	-	-
Unsecured Term loans from Bank	42.67	-	-	-
Total	183.28	153.03	-	-

22 Lease liabilities - non current financial liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Lease Liabilities	442.17	369.74	-	-
Total	442.17	369.74	-	-

23 Other financial liabilities - non current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Security deposits	5.00	-	-	-
Total	5.00	-	-	-

24 Provisions - non current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Provision for employee benefits	42.41	25.51	-	-
Total	42.41	25.51	-	-

25 Borrowings - current financial liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Secured Current maturities of Long term borrowing	44.75	41.35	-	-
Secured Loans repayable on demand from Banks	36.36	-	-	-
Unsecured Current maturities of Long term borrowing	26.06	-	-	-
Unsecured Loans from related parties	78.20	-	-	-
Total	185.37	41.35	-	-

26 Lease liabilities - current financial liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Lease Liabilities	54.99	22.39	-	-
Total	54.99	22.39	-	-

Handwritten signature and circular stamp of Gujarat Kidney And Super Speciality Limited, Vadodra.

GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

27 Trade Payables For Expense

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Total outstanding dues of Creditor of other than Micro Enterprise and small enterprise	367.89	240.21	346.76	346.72
Total	367.89	240.21	346.76	346.72

Trade Payables ageing schedule

As at 30 September 2024

Particulars	Unbilled	Undue	Outstanding for following periods from due date of payment				Total
			< 1 year	1-2 years	2-3 years	> 3 years	
(i) MSME	-	-	-	-	-	-	-
(ii) Others	-	-	318.92	21.14	17.44	10.39	367.89
(iii) Disputed dues- MSME	-	-	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-	-	-
Total							367.89

As at 31 March 2024

Particulars	Unbilled	Undue	Outstanding for following periods from due date of payment				Total
			< 1 year	1-2 years	2-3 years	> 3 years	
MSME	-	-	-	-	-	-	-
Others	-	-	207.02	23.81	4.43	4.95	240.21
Disputed dues- MSME	-	-	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-	-	-
Total							240.21

As at 31 March 2023

Particulars	Unbilled	Undue	Outstanding for following periods from due date of payment				Total
			< 1 year	1-2 years	2-3 years	> 3 years	
(i) MSME	-	-	-	-	-	-	-
(ii) Others	-	-	0.03	4.43	342.30	-	346.75
(iii) Disputed dues- MSME	-	-	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-	-	-
Total							346.75

As at 31 March 2022

Particulars	Unbilled	Undue	Outstanding for following periods from due date of payment				Total
			< 1 year	1-2 years	2-3 years	> 3 years	
MSME	-	-	-	-	-	-	-
Others	-	-	4.42	342.30	-	-	346.72
Disputed dues- MSME	-	-	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-	-	-
Total							346.72

Trade Payables ageing schedule note

In accordance with the applicable Financial Reporting Framework, our company has endeavored to present a detailed bifurcation of outstanding trade payables into amounts due to Micro, Small, and Medium Enterprises (MSMEs) and other creditors. However, due to the current limitations in our accounting system and the absence of requisite information from some of our suppliers, we are unable to accurately segregate the trade payables between MSMEs and others.

Management is in the process of updating the system to capture this information in the future. We have, however, ensured that all due diligence has been undertaken in identifying MSMEs where information was available, and appropriate steps have been taken to comply with regulatory requirements to the best of our ability.

This note is to inform the users of these financial statements that the amounts disclosed under trade payables may include amounts due to MSMEs, but a specific bifurcation is not currently available.

We are committed to rectifying this situation and providing the required disclosure in subsequent financial periods.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

28 Other current liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Advance received from customers	1.84	4.42	-	-
Directors remuneration payable	-	-	-	-
Statutory dues payable	54.89	34.01	-	0.03
Current Tax Liabilities, net - Subsidiary/Subsidiary Firms	28.51	-	-	-
Other expense payable	9.40	4.65	0.30	0.25
Salary payable	58.55	38.12	2.64	2.64
Total	153.19	81.20	2.94	2.92

29 Provisions - current

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Provision for employee benefits	4.46	2.26	-	-
Total	4.46	2.26	-	-

30 Current Tax Liabilities, net

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Provision for current tax liability, net of advance tax paid during the financial year	164.45	36.44	-	0.48
Total	164.45	36.44	-	0.48

31 Revenue From Operations

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Sale of healthcare services				
IPD Income	1,431.26	401.49	-	-
OPD Income	107.64	32.18	-	-
Other Services	7.70	1.03	-	-
Sale of Pharmacy	320.45	42.73	-	-
Total	1,867.05	477.43	-	-

31.1 Disaggregated revenue information

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Income from Sale of healthcare services				
Revenue from hospital & pharmacy services	1,867.05	477.43	-	-
Less: Inter Group Revenue	-	-	-	-
Total	1,867.05	477.43	-	-

31.2 Location of revenue recognition

All the business operations of the company are in India.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

31.3 Timing of revenue recognition

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Services transferred at a point of time	435.79	75.94	-	-
Services transferred over the period	1,431.26	401.49	-	-

31.4 Reconciliation of revenue recognised with the contracted price is as follows:

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Contracted price	1,935.14	497.96	-	-
Reduction towards variable consideration components	-	-	-	-
Discounts	-68.09	-20.53	-	-
Revenue recognised	1,867.05	477.43	-	-

31.5 Contract balances

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Trade receivables*	1,204.70	420.17	115.00	116.07
Contract liabilities (advance from patients)#	1.84	4.42	-	-

* Trade receivables are non-interest bearing and are generally on terms of 30 days.

Contract liabilities include advances received from patients for hospital services pending final billing.

32 Other Income

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Interest income	4.82	0.18	-	-
Profit on sale of property, plant and equipment	-	70.16	-	-
Interest Unwinding on Rent Deposit	0.29	0.05	-	-
Other non operating income	-	-	0.01	-
Robotic Arm Income	-	-	-	78.60
Total	5.11	70.39	0.01	78.60

33 Cost of medical consumables, drugs and surgical items

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Medical consumables, drugs and surgical items	27.00	-	-	-
Opening stock	147.16	57.69	-	-
Purchases	37.61	27.00	-	-
Less: Closing stock	-	-	-	-
Total	136.56	30.69	-	-
Total	136.56	30.69	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

34 Employee benefits expense

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Salaries and wages	304.87	82.12	-	4.80
Contribution to provident and other fund	11.86	3.91	-	-
Gratuity and Leave Encashment	6.93	8.34	-	-
Staff welfare expenses	17.35	12.92	-	-
Total	341.01	107.29	-	4.80

35 Finance costs

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Interest expenses				
On Other Borrowing	11.04	3.14	-	-
Unwinding of Discount on Lease	19.38	3.28	-	-
Other borrowing costs	1.15	0.30	-	-
Total	31.57	6.72	-	-

36 Depreciation and amortization expense

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Depreciation on Property, Plant and Equipments	129.32	28.25	-	57.40
Amortisation of Right of Use Assets	22.07	3.68	-	-
Total	151.39	31.93	-	57.40

37 Other expenses

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Auditors' Remuneration	1.00	1.00	0.40	0.30
Administrative expenses	10.62	4.41	-	-
Advertisement	7.56	5.43	-	1.51
Conveyance expenses	0.33	-	-	-
Insurance	0.48	-	-	-
Operating Expenses	100.24	23.71	-	-
Power and fuel	25.18	7.92	-	-
Professional fees	238.27	81.14	-	-
Rent	1.42	0.62	-	-
Rates and taxes	30.78	13.51	-	-
Travelling Expenses	3.88	1.32	-	-
Compliance Cost	0.68	-	0.23	0.92
Prepaid Lease Expense	0.44	0.07	-	-
Repairs and Maintenance	34.76	5.23	-	-
Total	455.64	144.36	0.63	2.73



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

38 Tax expenses

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Current tax	211.40	53.88	-	5.49
Deferred tax	-18.53	1.55	-	-1.82
Total	192.87	55.43	-	3.67

39 OCI that will not be reclassified to P&L

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Remeasurements of the defined benefit plans	3.59	-	-	-
Others				
Gain on Bargain Purchase	22.65	-	-	-
OCI Income tax of items that will not be reclassified to P&L	-0.90	-	-	-
Deferred Tax on Remeasurements				
Total	25.34	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

40 Earning per share

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Profit attributable to equity shareholders Rs. in Lakhs	563.13	171.40	-0.62	10.00
Weighted average number of Equity Shares (Pre Bonus)	16,09,550	10,00,000	10,00,000	10,00,000
Weighted average number of Equity Shares (Post Bonus)	4,55,22,205	3,50,00,000	3,50,00,000	3,50,00,000
Earnings per share basic (Rs) (Pre Bonus)	34.99	17.14	-0.06	1.00
Earnings per share basic (Rs) (Post Bonus)	1.24	0.49	-0.00	0.03
Earnings per share diluted (Rs) (Pre Bonus)	34.99	17.14	-0.06	1.00
Earnings per share diluted (Rs) (Post Bonus)	1.24	0.49	-0.00	0.03
Face value per equity share (Rs)	2.00	2.00	2.00	2.00

Note:

During the period ended September 30, 2024, vide shareholder's approval dated July 22, 2024, the company has done a stock split resulting in a change in face value per share from ₹10 per share to ₹2 per share. Subsequent to the period ended September 30, 2024, bonus shares were allotted in the ratio of 34 bonus shares for every 1 share held. As required under Ind AS 33 "Earnings per share" the effect of such split and bonus issues has been adjusted retrospectively for all the periods presented.

41 Defined Contribution Plan

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Employers Contribution to Provident Fund	15.92	3.91	-	-
Employers Contribution to Labour Welfare Fund	0.01	-	-	-

42 Defined Benefit Plans

(i) Gratuity

Reconciliation of present value of defined benefit obligation and fair value of assets

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Unfunded net liability recognized in balance sheet	46.87	27.77	-	-
Benefits paid by company	-0.37	-	-	-
Balance liability recognized in balance sheet	46.50	27.77		
Amount classified as:				
Short term provision	4.46	2.26	-	-
Long term provision	42.04	25.51	-	-

Expenses recognized in Profit and Loss Account

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Current service cost	5.98	27.77	-	-
Interest cost	0.96	-	-	-
Total expense recognised in Profit and Loss	6.94	27.77	-	-

Amount recognized in Other Comprehensive Income

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Due to Change in financial assumptions	0.78	-	-	-
Due to experience adjustments	-4.37	-	-	-
Total amount recognized in Other Comprehensive Income	-3.59	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Actuarial assumptions

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Discount Rate	0.07	0.07	-	-
Expected Rate of increase in Compensation Level	0.10	0.10	-	-

General Description of the Plan

The Entity operates gratuity plan through a trust wherein every employee is entitled to the benefit equivalent to fifteen days salary last drawn for each completed year of service. The same is payable on termination of service or retirement, whichever is earlier. The benefit vests after five years of continuous service. In case of some employees, the Entity's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

43 Contingent Liabilities

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Claims against the Company not acknowledged as debt (Direct Taxes)	6.40	-	-	-
Total	6.40	-	-	-

44 Leases**Breakup of Lease Liability**

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Current lease liabilities	54.99	22.39	-	-
Non current lease liabilities	442.17	369.74	-	-
Total	497.16	392.13	-	-

The movement in Lease Liability is as follows:

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Balance at the beginning	392.13	-	-	-
Acquisition through business combination	115.94	-	-	-
Addition during the year	-	393.90	-	-
Finance cost accrued	19.38	3.28	-	-
Payment of lease liabilities	-30.30	-5.05	-	-
Total	497.16	392.13	-	-

Contractual Lease Liabilities on undiscounted basis as follows

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Future minimum rental payables under non-cancellable operating lease				
- Not later than one year	96.78	30.30	-	-
- Later than one year and not later than five years	431.84	325.05	-	-
- Later than five years	191.54	251.66	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

45 Related Party Disclosure

(i) List of Related Parties	Relationship
Yashwantsingh Bharpoda	Director
Anitaben Bharpoda	Director
Pragnesh Bharpoda	Director
Bhartiben Bharpoda	Director
Bhavikaben Patel	Chief Financial Officer
Y M Bharpoda HUF	Relative
Raj Palmland Hospital Pvt Ltd	Subsidiary
Gujarat Surgical Hospital	Subsidiary Firm
Surya Hospital and ICU Center	Subsidiary Firm
New Gujarat Pharmacy	Proprietorship of Anitaben Bharpoda (Cease to exist w.e.f. 19.02.2024)
Kalpesh Bhagvatiprasad Joshi	Chief Executive Officer
Gold Cost Diagnostic Lab	Proprietorship of Bhartiben Bharpoda (Cease to exist w.e.f. 19.02.2024)
Surya Pharmacy - Borsad	Sister Concern of Subsidiary Firm
Wasim Raj	Director of Subsidiary
Ayyubhai Raj	Director of Subsidiary
Sama Pharmacy	Firm in Which Director is Partner
Gujarat Kidney and Superspeciality Hospital	Proprietorship of Pragnesh Bharpoda
Veenus Gehlot	EX-Company Secretary
Vivekkumar Patel	Relative of Director
Nikita Bharpoda	Relative of Director
Smit Medical Store	Firm in Which Director is Partner
Jagdish Thakkar	Independent Director
Udayan Kachchhi	Independent Director
Kairavi Shah	Independent Director

(ii) Related Party Transactions

Particulars	Relationship	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Remuneration to directors and KMP					
- Pragnesh Bharpoda	Director	90.00	20.69	-	-
- Bhartiben Bharpoda	Director	9.00	2.07	-	-
- Bhavikaben Patel	Chief Financial Officer	2.19	0.77	-	-
- Kalpesh Bhagvatiprasad Joshi	Chief Executive Officer	7.50	2.50	-	-
- Veenus Gehlot	EX-Company Secretary	1.26	-	-	-
Lease Installment					
- Pragnesh Bharpoda	Director	9.00	2.12	-	-
Unsecured Loan taken					
- Anitaben Bharpoda	Director	7.73	-	-	-
Purchase of Pharmacy					
- New Gujarat Pharmacy	Proprietorship of Anitaben Bharpoda (Cease to exist w.e.f. 19.02.2024)	-	27.33	-	-
- Smit Medical Store	Firm in Which Director is Partner	3.26	-	-	-
Business transfer collectibles (Credits)					
- Pragnesh Bharpoda	Director	604.41	161.72	-	-
Business transfer Collectibles					
- Pragnesh Bharpoda	Director	515.57	221.98	-	-
Unsecured Loan paid					
- Anitaben Bharpoda	Director	7.00	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

(All amounts are ₹ in Lakhs, unless otherwise stated)

Particulars	Relationship	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
Creditors acquired through business acquisition					
- Gold Cost Diagnostic Lab	Proprietorship of Bhartiben Bharpoda (Cease to exist w.e.f. 19.02.2024)	-	110.51	-	-
- Sama Pharmacy	Firm in Which Director is Partner	51.83	-	-	-
Unsecured loan acquired through business acquisition					
- Wasim Raj	Director of Subsidiary	29.45	-	-	-
- Surya Pharmacy - Borsad	Sister Concern of Subsidiary Firm	9.25	-	-	-
- Ayyubhai Raj	Director of Subsidiary	10.20	-	-	-
Robotic Arm Income					
- Gujarat Kidney and Superspeciality Hospital	Proprietorship of Pragnesh Bharpoda	-	-	-	78.60
Professional Fees					
- Vivekkumar Patel	Relative of Director	12.00	-	-	-
- Nikita Bharpoda	Relative of Director	5.00	3.00	-	-
Investment					
- Gujarat Surgical Hospital	Subsidiary Firm	9.00	-	-	-
- Raj Palmland Hospital Pvt Ltd	Subsidiary	124.62	-	-	-
- Surya Hospital and ICU Center	Subsidiary Firm	17.83	-	-	-

(iii) Related Party Balances

Particulars	Relationship	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Other expense payable					
- Pragnesh Bharpoda	Director	2.14	-	-	-
Salary Payable					
- Bhartiben Bharpoda	Director	3.42	85.08	-	-
- Bhavikaben Patel	Chief Financial Officer	0.37	0.37	-	-
- Kalpesh Bhagvatiprasad Joshi	Chief Executive Officer	1.23	1.18	-	-
- Veenus Gehlot	EX-Company Secretary	0.21	-	-	-
Trade Payable					
- New Gujarat Pharmacy	Proprietorship of Anitaben Bharpoda (Cease to exist w.e.f. 19.02.2024)	0.33	0.33	-	-
- Gold Cost Diagnostic Lab	Proprietorship of Bhartiben Bharpoda (Cease to exist w.e.f. 19.02.2024)	-	83.01	-	-
- Sama Pharmacy	Firm in Which Director is Partner	51.83	-	-	-
- Vivekkumar Patel	Relative of Director	2.70	-	-	-
Business transfer Collectibles					
- Pragnesh Bharpoda	Director	-	60.26	-	-
Unsecured Loans from related parties					
- Pragnesh Bharpoda	Director	28.58	-	-	-
- Anitaben Bharpoda	Director	0.73	-	-	-
- Wasim Raj	Director of Subsidiary	29.45	-	-	-
- Ayyubhai Raj	Director of Subsidiary	10.20	-	-	-
- Surya Pharmacy - Borsad	Sister Concern of Subsidiary Firm	9.25	-	-	-
Trade Receivable					
- Pragnesh Bharpoda	Director	-	-	115.00	116.07



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

46 Financial Instrument

Financial Risk Management - Objectives and Policies

The Company's activities expose it to various financial risks, including market risk, credit risk and liquidity risk. The Company's risk management assessment and policies and processes are established to identify and analyse the risks faced by the Company by setting appropriate limits and controls and monitoring such risks. The policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Company's risk management is governed by policies and approved by the board of directors. Company identifies, evaluates and hedges financial risks in close co-operation with the Company's operating units. The company has policies for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments.

The audit committee oversees how management monitors compliance with the company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

A. Financial Assets and Liabilities

Particulars	As at 30 September 2024			As at 31 March 2024		
	Amortised Cost	FVTPL	FVTOCI	Amortised Cost	FVTPL	FVTOCI
Assets Measured at						
Trade receivables	1,204.71	-	-	420.17	-	-
Cash and cash equivalent	422.54	-	-	97.04	-	-
Other bank balances	240.68	-	-	20.46	-	-
Current Other financial assets (A)	4.82	-	-	0.18	-	-
Other financial assets	34.49	-	-	5.62	-	-
Total	1,907.23	-	-	543.48	-	-
Liabilities Measured at						
Borrowings	368.65	-	-	194.39	-	-
Trade payables	367.89	-	-	240.21	-	-
Lease liabilities	497.16	-	-	392.13	-	-
Non current Other financial liabilities (A)	5.00	-	-	-	-	-
Total	1,238.70	-	-	826.73	-	-

Financial Assets and Liabilities

Particulars	As at 31 March 2023			As at 31 March 2022		
	Amortised Cost	FVTPL	FVTOCI	Amortised Cost	FVTPL	FVTOCI
Assets Measured at						
Trade receivables	115.00	-	-	116.07	-	-
Cash and cash equivalent	0.35	-	-	0.34	-	-
Total	115.35	-	-	116.41	-	-
Liabilities Measured at						
Trade payables	346.75	-	-	346.72	-	-
Total	346.75	-	-	346.72	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

B. Market Risk

Market risk - is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risks: interest rate risk, currency risk and other price risk.

Financial instruments affected by market risk includes investments, trade payables, trade receivables and loans.

C. Credit Risk

Credit risk - is the risk of loss that may arise on outstanding financial instruments if a counterparty default on its obligations. The Company's exposure to credit risk arises majorly from trade receivables and other financial assets. Other financial assets are bank deposits with banks and hence, the Company does not expect any credit risk with respect to these financial assets.

With respect to other financial assets, the Company has constituted teams to review the receivables on periodic basis and to take necessary mitigations, wherever required. The Company creates allowance for all unsecured receivables based on lifetime expected credit loss. At the balance sheet date, there was no significant concentration of credit risk and exposure thereon.

D. Liquidity Risk

Liquidity risk - is the risk that the Company will not be able to meet the financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both, normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

With significant investments in fixed deposits, cash in hand and available borrowing lines, the Company does not envisage any material effect on its liquidity.

E. Capital Management

For the purpose of the Company's Capital Management, capital includes issued capital and other equity reserves, long term funds attributable to the Equity Shareholders of the Company. The primary objective of the Company's Capital Management is to maximise shareholders value and keep the debt equity ratio within acceptable range. The Company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants. The Company monitors capital using adjusted net debt to equity ratio. For this purpose, adjusted net debt is defined as total debt less cash and bank balances.

Capital Management

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Total Borrowings	368.65	194.39	-	-
Less: Cash and cash equivalents	422.54	97.04	-	-
Net Debts (A)	-53.89	97.35	-	-
Total Equity (B)	19.17	10.80	-	-
Capital Gearing Ratio (A/B)	-0.03	0.09	-	-

47 Earnings in Foreign Currencies

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Export of Goods calculated on FOB basis	-	-	-	-
Royalty, know-how, professional and consultation fees	-	-	-	-
Interest and dividend	-	-	-	-
Other income, indicating the nature thereof	-	-	-	-
Total	-	-	-	-

48 Expenditure made in Foreign Currencies

Particulars	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Royalty	-	-	-	-
Know-how	-	-	-	-
Professional and Consultation Fees	-	-	-	-
Interest	-	-	-	-
Other Matters	-	-	-	-
Total	-	-	-	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)


49 Ratio Analysis

Particulars	Numerator/Denominator	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
(a) Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	2.18	1.59	0.33	0.33
(b) Debt-Equity Ratio	$\frac{\text{Total Debts}}{\text{Equity}}$	0.18	0.18	-	-
(c) Debt Service Coverage Ratio	$\frac{\text{Earning available for Debt Service}}{\text{Interest + Instalments}}$	28.96	26.56	-	-
(d) Return on Equity Ratio	$\frac{\text{Profit after Tax}}{\text{Shareholder's Equity}}$	27.32%	15.86%	-1.67%	26.56%
(e) Inventory turnover ratio	$\frac{\text{Total Turnover}}{\text{Inventories}}$	49.64	17.68	-	-
(f) Trade receivables turnover ratio	$\frac{\text{Total Turnover}}{\text{Account Receivable}}$	1.55	1.14	-	-
(g) Net capital turnover ratio	$\frac{\text{Total Turnover}}{\text{Working Capital}}$	1.70	1.92	-	-
(h) Net profit ratio	$\frac{\text{Net Profit}}{\text{Total Turnover}}$	30.16%	35.90%	-	-
(i) Return on Capital employed	$\frac{\text{Earning before interest and taxes}}{\text{Capital Employed}}$	26.73%	9.79%	-1.70%	-172.46%
(j) Trade Payable turnover ratio	$\frac{\text{Total Turnover}}{\text{Account Payable}}$	5.08	1.99	-	-

The ratios provided in the table above are calculated based on the closing values of the relevant Statement of Consolidated Assets and Liabilities items. The closing values reflect the financial position of the company at the end of the relevant period, as presented in the financial statements.

% Change in Ratios

Particulars	As at 31 March 2024	As at 31 March 2023	Reasons
(a) Current Ratio	59%	-67%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(b) Debt-Equity Ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(c) Debt Service Coverage Ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Particulars	As at 31 March 2024	As at 31 March 2023	Reasons
(d) Return on Equity Ratio	116%	-102%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(e) Inventory turnover ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(f) Trade receivables turnover ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(g) Net capital turnover ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(h) Net profit ratio	100%	0%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.
(i) Return on Capital employed	110%	-102%	The variations in ratios primarily arise due to the recognition of newly acquired assets, liabilities, and business operations pursuant to Business acquisition of the business of the promoter w.e.f. 19.02.2024 leading to material changes in financial metrics such as revenue growth, profitability, return on assets/equity.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

50 Subsequent Events and Other Statutory Disclosures

1 Note on Subsequent Events

The Company has evaluated subsequent events that occurred after the reporting period up to [date of approval of financial statements].
The following material subsequent events have been identified:

Revision of Lease Agreement:

Pursuant to a new lease agreement dated February 4, 2025, the terms of the lease for the Registered Office of the Company located at Jetalpur Road, Vadodara have been revised. The lease term has been modified to one year, effective from February 4, 2025.

Bonus Issue of Equity Shares:

On February 6, 2025, the Company allotted bonus Equity Shares to each of its existing shareholders in the ratio of 34:1 (i.e., 34 Equity Shares for each Equity Share held) as of the record date, February 4, 2025. This issuance has resulted in a significant increase in the Company's outstanding share capital.

Business Acquisitions:

On February 13, 2025, the Company entered into Business Transfer Agreements to acquire the businesses of:

- Ashwini Medical Centre for a consideration of ₹1,400 lakhs
- Ashwini Medical Store for a consideration of ₹100 lakhs

These acquisitions are expected to enhance the Company's operational capabilities and expand its market presence in the healthcare sector.

Except for the above matters, no other material subsequent events have occurred that require adjustments to disclosure for the period ended September 30, 2024.

2 Other Statutory Disclosures as per the Companies Act, 2013

- (i) The Group has used the borrowings from banks and financial institutions for the specific purpose for which it was taken at the balance sheet date.
- (ii) The Group neither has any immovable property nor any title deeds of Immovable Property not held in the name of the Group.
- (iii) During the financial year, the Group has not revalued any of its Property, Plant and Equipment, Right of Use Asset and Intangible Assets.
- (iv) The Group has not granted any Loans or Advances to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are:
 - (a) repayable on demand or
 - (b) without specifying any terms or period of repayment
- (v) The Group does not have any intangible assets under development as at 31 March 2022, and hence disclosure under Schedule III is not applicable for that period.
- (vi) There are no proceedings which have been initiated or pending against the Group for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
- (vii) With respect to borrowings from banks or financial institutions on the basis of security of current assets, the returns or statements comprising the information on unhedged foreign currency exposure and unaudited provisional financial statements filed by the Group with such banks are in agreement with the books of account of the Group.
- (viii) The Group has not been declared as a wilful defaulter by any bank or financial Institution or other lender.
- (ix) The Group does not have any charges or satisfaction yet to be registered with ROC beyond the statutory period.
- (x) The Group has Subsidiary/Subsidiary Firms and complies with clause (87) of Section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.
- (xi) The Group has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall :-
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (xii) The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:-
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (xiii) The Group neither has traded nor invested in Crypto currency or Virtual Currency during the financial years.
- Xiv) The Group does not have any investment properties as defined in Ind AS 40.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

51 Additional Information required under Schedule III to the Companies Act, 2013 of entities consolidated as Subsidiary/Subsidiary Firms:

Name of the entity in the group	Net assets (total assets minus total liabilities)		Share in profit or (loss)		Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount
Parent								
Gujarat Kidney and Superspeciality Limited								
30 September 2024	84.55%	1,742.78	0.00%	-	0.00%	-	0.00%	-
31 March 2024	100.00%	1,080.43	0.00%	-	0.00%	-	0.00%	-
31 March 2023	100.00%	37.02	0.00%	-	0.00%	-	0.00%	-
31 March 2022	100.00%	37.65	0.00%	-	0.00%	-	0.00%	-
Indian Subsidiary/Subsidiary Firms								
Raj Palmland Hospital Private Limited								
30 September 2024	7.14%	147.28	0.00%	-	0.00%	-	0.00%	-
31 March 2024	0.00%	110.31	0.00%	-	0.00%	-	0.00%	-
31 March 2023	0.00%	58.14	0.00%	-	0.00%	-	0.00%	-
31 March 2022	0.00%	120.74	0.00%	-	0.00%	-	0.00%	-
Gujarat Surgical Hospital								
30 September 2024	0.44%	9.00	0.00%	-	0.00%	-	0.00%	-
31 March 2024	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2023	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2022	0.00%	-	0.00%	-	0.00%	-	0.00%	-
Surya Hospital and Icu								
30 September 2024	0.86%	17.83	0.00%	-	0.00%	-	0.00%	-
31 March 2024	0.00%	28.43	0.00%	-	0.00%	-	0.00%	-
31 March 2023	0.00%	35.24	0.00%	-	0.00%	-	0.00%	-
31 March 2022	0.00%	31.03	0.00%	-	0.00%	-	0.00%	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

51 Additional Information required under Schedule III to the Companies Act, 2013 of entities consolidated as Subsidiary/Subsidiary Firms (Continued)

Name of the entity in the group	Net assets (total assets minus total liabilities)		Share in profit or (loss)		Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount	As % of consolidated net assets	Amount
Non-Controlling Interest in all Subsidiary/Subsidiary Firms								
30 September 2024	7.01%	144.48	0.00%	-	0.00%	-	0.00%	-
31 March 2024	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2023	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2022	0.00%	-	0.00%	-	0.00%	-	0.00%	-
Eliminations & Consolidation adjustments								
30 September 2024	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2024	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2023	0.00%	-	0.00%	-	0.00%	-	0.00%	-
31 March 2022	0.00%	-	0.00%	-	0.00%	-	0.00%	-
Total								
30 September 2024	100.00%	2,061.37	0.00%	-	0.00%	-	0.00%	-
31 March 2024	100.00%	1,080.43	0.00%	-	0.00%	-	0.00%	-
31 March 2023	100.00%	37.02	0.00%	-	0.00%	-	0.00%	-
31 March 2022	100.00%	37.65	0.00%	-	0.00%	-	0.00%	-



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

52 Non-Controlling Interest**(a) Raj Palmland Hospital Private Limited**

The Company holds ownership interest of 51% in Raj Palmland Hospital Private Limited as at 30 September 2024. The summarized financial information of the Subsidiary is provided below. This information is based on standalone financial statement of the Subsidiary:

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Income	386.87	731.16	553.90
Expenses	316.30	680.03	619.33
Profit Before Tax	70.57	51.13	-65.43
Tax Expense	17.26	-1.04	-2.84
Profit / (Loss) for the Year	53.31	52.17	-62.59
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	53.31	52.17	-62.59
Other Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-
Total Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-

Summarized Balance Sheet

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non-Current Asset	190.92	186.08	218.37
Current Asset	421.60	231.77	247.84
Non-Current Liabilities	86.05	104.61	127.73
Current Liabilities	237.69	202.93	280.34
Total Equity	288.78	110.31	58.14
- attributable to the owners of the Company	147.28	-	-
- attributable to the non-controlling interest	141.50	110.31	58.14

Summarized Cash Flow Statement

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Net cash generated from operating activities (A)	35.23	86.74	-21.90
Net cash used in investing activities (B)	-23.85	-11.13	-49.44
Net cash generated used in financing activities (C)	-	-	-
Net increase in cash and cash equivalents (A+B+C)	11.38	75.61	-71.34

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non Controlling Interest	141.50	110.31	58.14



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

(b) Gujarat Surgical Hospital

The Company holds ownership interest of 90% in Gujarat Surgical Hospital as at 30 September 2024. The summarized financial information of the Subsidiary Firms is provided below. This information is based on standalone financial statement of the Subsidiary Firms:

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Income	79.29	133.12	166.37
Expenses	46.48	116.75	127.14
Profit Before Tax	32.81	16.37	39.23
Tax Expense	10.23	5.16	12.30
Profit / (Loss) for the Year	22.58	11.21	26.93
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	22.58	11.21	26.93
Other Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-
Total Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-


Summarized Balance Sheet

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non-Current Asset	39.43	43.29	60.16
Current Asset	91.46	85.78	102.29
Non-Current Liabilities	-	-	-
Current Liabilities	81.46	74.39	81.53
Total Equity	49.43	54.68	80.92
- attributable to the owners of the Company	44.49	-	-
- attributable to the non-controlling interest	4.94	54.68	80.92

Summarized Cash Flow Statement

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Net cash generated from operating activities (A)	27.47	34.15	59.01
Net cash used in investing activities (B)	-	-	-2.94
Net cash generated used in financing activities (C)	-27.53	-29.74	-59.23
Net increase in cash and cash equivalents (A+B+C)	-0.06	4.41	-3.16

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non Controlling Interest	4.94	54.68	80.92



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

(c) Surya Hospital and ICU

The Company holds ownership interest of 90% in Surya Hospital and ICU as at 30 September 2024. The summarized financial information of the Subsidiary Firms is provided below. This information is based on standalone financial statement of the Subsidiary Firms:

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Income	62.84	106.64	82.40
Expenses	35.86	77.76	84.61
Profit Before Tax	26.98	28.88	-2.21
Tax Expense	8.43	10.08	-0.64
Profit / (Loss) for the Year	18.55	18.80	-1.57
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	18.55	18.80	-1.57
Other Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-
Total Comprehensive Income / (Loss)	-	-	-
- attributable to the owners of the Company	-	-	-
- attributable to the non-controlling interest	-	-	-

Summarized Balance Sheet

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non-Current Asset	108.77	116.45	135.61
Current Asset	21.32	13.27	7.21
Non-Current Liabilities	61.92	76.55	83.96
Current Liabilities	110.28	101.29	107.58
Total Equity	-42.11	-48.12	-48.72
- attributable to the owners of the Company	-37.90	-	-
- attributable to the non-controlling interest	-4.21	-48.12	-48.72

Summarized Cash Flow Statement

Particulars	For the Period ended 30th September 2024	For the Year ended 31st March 2024	For the Year ended 31st March 2023
Net cash generated from operating activities (A)	41.47	56.57	14.23
Net cash used in investing activities (B)	-	0.08	-
Net cash generated used in financing activities (C)	-33.41	-48.60	-12.28
Net increase in cash and cash equivalents (A+B+C)	8.06	8.05	1.95

Particulars	As at 30th September 2024	As at 31st March 2024	As at 31st March 2023
Non Controlling Interest	-4.21	-48.12	-48.72



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

53 Restated Tax Shelter

Particulars	For the period ended 30 September 2024	For the year ended 31 March 2024	For the year ended 31 March 2023	For the year ended 31 March 2022
a. Amount recognized in the statement of profit and loss				
Current Tax	211.40	53.88	-	5.49
Deferred tax attributable to temporary differences	-18.53	1.55	-	-1.82
Tax Expense for the year	192.87	55.43	-	3.67
b. Amount recognized in other comprehensive income				
Remeasurement of the defined benefit plans	3.59	-	-	-
Remeasurement of Fair Value Investments	-	-	-	-
Income tax relating to these items	-0.90	-	-	-
c. Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for 30 September 2024, 31 March 2024, 31 March 2023, 31 March 2022 and 01 April 2021.				
Reconciliation of Effective tax rate				
Accounting profit before income tax	756.00	226.83	-0.62	13.67
Deductible expenses for tax purposes:	71.75	16.77	0.01	49.98
Non-deductible expenses for tax purposes:	155.70	4.04	0.63	58.13
Total- PGBP	839.96	214.09	-	21.82
Capital Gain	-	-	-	-
Short Term Capital Gain	-	-	-	-
Long Term Capital Gain	-	-	-	-
Gross Total Income	839.96	214.09	-	21.82
Less: Deductions Under Chapter-VIA	-	-	-	-
Total Income	839.96	214.09	-	21.82
Tax Payable	211.40	53.88	-	5.49
Effective income tax rate	27.96%	23.75%	0.00%	40.17%
d. Deferred tax relates to the following				
Property, Plant and Equipment	14.02	-1.99	-	1.87
Lease Liability	2.81	0.48	-	-
Gratuity	1.75	-	-	-
Other timing difference	-0.04	-0.04	-	-0.05
Net Deferred Tax Liability	18.53	-1.55	-	1.82



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

Notes forming part of the Restated Consolidated Financial Information

(All amounts are ₹ in Lakhs, unless otherwise stated)

54 OTHER FINANCIAL INFORMATION

	As at 30 September 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
1 Net Worth (A)	2,038.72	1,080.43	37.02	37.65
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA)	933.85	195.09	-0.63	-7.53
Restated Profit after tax	563.13	171.40	-0.62	10.00
Add: Prior Period Item	-	-	-	-
Adjusted Profit after Tax (B)	563.13	171.40	-0.62	10.00
Number of Equity Share outstanding as on the End of Year/Period (C)	16,09,550	10,00,000	10,00,000	10,00,000
Weighted average no of Equity shares as on the end of the period year (D)				
- Pre Bonus (D(i))	16,09,550	10,00,000	10,00,000	10,00,000
- Post Bonus (D(ii))	4,55,22,205	3,50,00,000	3,50,00,000	3,50,00,000
Face Value per Share				
Restated Basic & Diluted Earnings Per Share (Rs.) (B/D)				
- Pre Bonus (B/D(i))	34.99	17.14	(0.06)	1.00
- Post Bonus (B/D(ii))	1.24	0.49	(0.00)	0.03
Return on Net worth (%) (B/A)	27.62%	15.86%	-1.68%	26.55%
Net asset value per share (A/D(i)) (Pre Bonus)	128.07	108.04	3.70	3.77
Net asset value per share (A/D(ii)) (Post Bonus)	4.53	3.09	0.11	0.11

Notes:-

(i) Basic Earnings per Share

Restated Profit after Tax available to equity shareholders

Weighted average number of equity shares outstanding at the end of the year

(ii) Net Asset Value (NAV) per Equity Share

Restated Net Worth of Equity Share Holders

Number of equity shares outstanding at the end of the year / period

(iii) Return on Net worth (%)

Restated Profit after Tax available to equity shareholders


Restated Net Worth of Equity Share Holders

2 EBITDA represents Earnings (or Profit/ (Loss)) before Finance Costs, Income Taxes, and Depreciation and Amortization Expenses. Extraordinary and Exceptional Items have been considered in the calculation of EBITDA as they were expense items.

3 Net Profit as restated, as appearing in the Statement of Profit and Losses, has been considered for the purpose of computing the above ratios. These ratios are computed on the basis of the Restated Financial Information of the Company.

4 Earnings per share calculations are done in accordance with Indian Accounting Standard (Ind AS) 33 Earnings per Share, issued by the Institute of Chartered Accountants of India.

5 Weighted average number of Equity Shares is the number of Equity Shares outstanding at the beginning of the period adjusted by the number of Equity Shares issued during period multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the period.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information****(All amounts are ₹ in Lakhs, unless otherwise stated)****55 STATEMENT OF CAPITALISATION**

PARTICULARS	Pre-Offer	Post-Offer
Debt		
- Short Term Debt	114.56	114.56
- Long Term Debt	254.09	254.09
Total Debt	368.65	368.65
Shareholders' Fund (Equity)		
- Share Capital	32.19	
- Reserves & Surplus	1,884.71	
- Less: Miscellaneous Expenses not W/off	-	
Total Shareholders' Fund (Equity)	1,916.90	
Long Term Debt / Equity (In Ratio)	0.13	
Total Debt / Equity (In Ratio)	0.19	

Notes:-

- 1 Short Term Debts represent which are expected to be paid/payable within 12 months and exclude installments of Term Loans repayable within 12 months.
- 2 Long Term Debts represent debts other than Short Term Debts as defined above but include installments of Term Loans repayable within 12 months grouped under other current liabilities.
- 3 The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at 30th September, 2024.
- 4 The post issue capitalization will be determined only after the completion of the allotment of Equity Shares.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**


(All amounts are ₹ in Lakhs, unless otherwise stated)

56 Financial Indebtedness

Particulars	Sanction Limit	Outstanding as on 30th September, 2024	Outstanding as on 31st March, 2024	Outstanding as on 31st March, 2023	Outstanding as on 31st March, 2022
Secured	182.96	179.01	194.38	-	-
Secured - Subsidiary/Subsidiary Firms	143.28	61.05	NA	NA	NA
Unsecured- From Bank	-	-	-	-	-
Unsecured- From Bank Subsidiary/Subsidiary Firms	105.32	50.38	NA	NA	NA
Unsecured- From Related Party	-	29.31	-	-	-
Unsecured- From Related Party- Subsidiary/Subsidiary Firms	-	48.70	NA	NA	NA
Total	431.56	368.45	194.38	-	-

56.1: Restated Statement of Details regarding Loan From Bank (Secured and Unsecured) - Gujarat Kidney and Super Speciality Limited**Long Term Borrowings (secured)**

Sr No.	Lender	Nature of Facility	Sanction Limit	Outstanding as on 30th September, 2024	Rate of Interest/Margin	Repayment Term	Security/ Principal terms and conditions	Collateral Security/ other Condition
1	HDFC Bank Limited	Healthcare Equipment Loan	131.15	131.15	9.55 % p.a.	Repayable in 76 Monthly Installments	CATH LAB Allengers	Personal guarantee of all director
2	HDFC Bank Limited	Healthcare Equipment Loan	51.81	47.86	9.55 % p.a.	Repayable in 24 Monthly Installments	CATH LAB Phillips	Personal guarantee of all director



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Short Term Borrowing (Secured and Unsecured)

Sr No.	Lender	Nature of Facility	Sanction Limit	Outstanding as on 30th September, 2024	Rate of Interest/Margin	Repayment Terms	Security/ Principal terms and conditions	Collateral Security/ other Condition
1	Anita Bharpoda	Unsecured Borrowing	-	28.58	NA	Repayable on demand	Unsecured	Unsecured
2	Dr Pragnesh Bharpoda	Unsecured Borrowing	-	0.73	NA	Repayable on demand	Unsecured	Unsecured

56.2: Restated Statement of Details regarding Loan From Bank (Secured and Unsecured) - Subsidiary/Subsidiary Firms**Long Term Borrowings (secured)**

Sr No.	Lender	Nature of Facility	Sanction Limit	Outstanding as on 30th September, 2024	Rate of Interest/Margin	Repayment Term	Security/ Principal terms and conditions	Collateral Security/ other Condition
1	The Federal Bank Ltd	Vehicle Loan	7.00	5.63	MCLR + 4.05%	Repayable in 60 Monthly Installments	Secured on Hypothecation of Maruti Suzuki Eeco	Fixed Deposit of Rs. 12.5 Lakhs in the name of Borrower
2	The Federal Bank Ltd	Vehicle Loan	4.71	0.71	Repo Rate + 4.50%	Repayable in 36 Monthly Installments	Secured on Hypothecation of Maruti Suzuki Eeco	Fixed Deposit of Rs. 12.5 Lakhs in the name of Borrower
3	HDFC Bank	Vehicle Loan	31.57	18.35	9.29%	Repayable in 60 Monthly Installments	Secured on Hypothecation of Vehicle	NA

Long Term Borrowings (Unsecured)

Sr No.	Lender	Nature of Facility	Sanction Limit	Outstanding as on 30th September, 2024	Rate of Interest/Margin	Repayment Term	Security/ Principal terms and conditions	Collateral Security/ other Condition
1	HDFC Bank	Self Employed Professional Loan	60.32	35.16	10.75%	Repayable in 60 Monthly Installments	Unsecured	Unsecured
2	HDFC Bank Limited	Unsecured Term Loan	45.00	15.22	10.50%	Repayable in 60 Monthly Installments	Unsecured	Personal Guarantee by Partners




GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Short Term Borrowing (Secured and Unsecured)

Sr No.	Lender	Nature of Facility	Sanction Limit	Outstanding as on 30th September, 2024	Rate of Interest/Margin	Repayment Terms	Security/ Principal terms and conditions	Collateral Security/ other Condition
1	The Federal Bank Ltd	OD - QUICK BIZ	50.00	26.30	10.70% P.a (One Year MCLR + 2.4%)	On demand and Subject to Annual Renewal	Hypothecation of entire book debts	Fixed Deposit of Rs. 12.5 Lakhs in the name of Borrower
2	Aiyub Raj	Unsecured Borrowing	-	10.00	NA	Repayable on demand	Unsecured	Unsecured
3	Wasim Raj	Unsecured Borrowing	-	29.45	NA	Repayable on demand	Unsecured	Unsecured
4	Surya Pharmacy - Borsads	Unsecured Borrowing	-	9.25	NA	Repayable on demand	Unsecured	Unsecured
5	Axis Bank Limited	Overdraft	50.00	10.06	10.00% P.a.	On demand and Subject to Annual Renewal	Personal Guarantee by Partners	



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

Note 57: First Time Adoption of Ind AS

The Company has prepared the opening balance sheet as per Ind AS as of April 1, 2021 (the transition date) by recognising all assets and liabilities whose recognition is required by Ind AS, by reclassifying items from previous GAAP to Ind AS as required under Ind AS, and applying Ind AS in measurement of recognised assets and liabilities. However, this principle is subject to the certain mandatory exceptions under Ind AS 101 and certain optional exemptions permitted under Ind AS 101 availed by the Company as detailed below:

1 Exemptions and exceptions availed

Set out below are the applicable Ind AS 101 optional exemptions and mandatory exceptions applied in the transition from previous GAAP to Ind AS.

1.1 Ind AS optional exemptions

1.1.1 Deemed cost

Ind AS 101 permits a first-time adopter to measure all of its property, plant and equipment as recognised in the Financial Statements as at the date of transition to Ind AS at fair value or previous GAAP carrying value and use that as its deemed cost as at the date of transition. This exemption can also be used for intangible assets covered by Ind AS 38 "Intangible Assets"; and investment property, accounted for in accordance with the cost model in Ind AS 40, Investment Property .

Accordingly, the company has elected to use previous GAAP carrying value as deemed cost for property, plant and equipment (PPE) and Investment properties.

1.2 Ind AS mandatory exceptions

1.2.1 Estimates

An entity's estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

The company has not made any changes to the estimates made in accordance with Previous GAAP.

1.2.2 De-recognition of financial assets and liabilities:

The Company has elected to apply the de-recognition provisions of Ind AS 109 prospectively from the date of transition to Ind AS.

1.2.3 Classification and measurement of financial assets

Ind AS 101 requires an entity to assess classification and measurement of financial assets (other than equity instruments) on the basis of the facts and circumstances that exist at the date of transition to Ind AS. Consequently, the Company has applied the above assessment based on facts and circumstances exist at the transition date.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

2.1 Reconciliations between previous GAAP and Ind AS

Ind AS 101 requires an entity to reconcile equity and total comprehensive income prior periods. The following tables represent the reconciliations from previous GAAP to Ind AS.

The presentation requirements under previous GAAP differs from Ind AS and hence the previous GAAP information has been regrouped for ease of reconciliation with Ind AS. The regrouped previous GAAP information is derived based on the audited financial statements of the Company for the year ended 31 March 2024.

Reconciliation of Equity March 31, 2024

Particulars	Restated as per previous GAAP	Effects of transition to Ind-AS	Ind AS
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	973.84		973.84
(b) Intangible Assets			
(c) Capital Work in Progress			
(d) Right -Of- Use Assets		390.22	390.22
(e) Financial Assets			
i. Investments			
ii. Other Financial Assets	13.00	-7.38	5.62
(f) Other Non-Current Assets	0.45	6.91	7.35
(g) Deferred Tax Asset (Net)	9.03	-6.39	2.64
Total Non Current Assets	996.31		1,379.68
Current assets			
(a) Inventories	27.00	-	27.00
(b) Financial Assets	-	-	
(i) Trade Receivables	420.17	-	420.17
(ii) Cash and Cash Equivalents	97.04	-	97.04
(iii) Bank Balances Other than (ii) above	20.46	-	20.46
(iv) Other Financial Asset	0.18	-	0.18
(c) Current Tax Asset (Net)	-	-	
(d) Other Current Assets	108.02	-	108.02
Total Current Assets	672.88		672.88
Total Assets	1,669.19		2,052.56



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information
(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of Equity March 31, 2024

Particulars	Restated as per previous GAAP	Effects of transition to Ind-AS	Ind AS
Equity and Liabilities			
Equity			
(a) Equity Share capital	20.00	-	20.00
(b) Other Equity	1,069.20	-8.77	1,060.43
Total Equity	1,089.20		1,080.43
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	153.04	-	153.04
(ii) Lease liabilities	-	369.74	369.74
(iii) Other Financial Liability	-	-	-
(b) Provisions	25.51	-	25.51
(c) Deferred Tax liabilities (Net)	-	-	-
Total Non Current Liabilities	178.54		548.28
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	41.35	-	41.35
(ii) Lease liabilities	-	22.39	22.39
(iii) Trade Payables			
Total outstanding dues of micro enterprises and small enterprises			
Total outstanding dues of creditors other than micro enterprises and small enterprise	240.21	-	240.21
(iv) Other Financial Liabilities	-	-	-
(b) Other Current Liabilities	81.20	-	81.20
(c) Provision	2.26	-	2.26
(d) Current Tax Liabilities (Net)	36.44	-	36.44
Total Current Liabilities	401.45		423.85
Total Liabilities	580.00		972.13
Total Equity and Liabilities	1,669.19		2,052.56



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of total comprehensive income for the year ended 31 March 2024

Particulars	Regrouped & Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Income			
Revenue from operations (net)	477.43	-	477.43
Other income	70.35	0.05	70.39
Total Income (I)	547.78		547.83
Expenses			
Purchase of Traded Goods	57.70	-	57.70
Changes in stock of finished goods, work in progress	-27.00	-	-27.00
Employee benefits expense	97.23	-	97.23
Finance costs	3.44	3.28	6.72
Depreciation expense	28.25	3.68	31.93
Other expenses	193.91	-39.49	154.42
Total Expenses (II)	353.53		321.00
Profit before exceptional items and tax (I-II)	194.25		226.83
Exceptional Items			
Profit before tax	194.25		226.83
Tax expense:			
Current tax	53.88	-	53.88
MAT	-	-	-
Deferred tax	-4.99	6.54	1.55
Total Tax expense	48.89		55.43
Profit for the year	145.36		171.40
Other Comprehensive Income			
A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:			
Remeasurement of gains (losses) on defined benefit plans			
Income tax effect			
Total Other Comprehensive Income		-	-
Total Comprehensive Income For The Period	145.36		171.40



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

2.2 Reconciliations between previous GAAP and Ind AS

Ind AS 101 requires an entity to reconcile equity and total comprehensive income prior periods. The following tables represent the reconciliations from previous GAAP to Ind AS.

The presentation requirements under previous GAAP differs from Ind AS and hence the previous GAAP information has been regrouped for ease of reconciliation with Ind AS. The regrouped previous GAAP information is derived based on the audited financial statements of the Company for the year ended 31 March 2023.

Reconciliation of Equity March 31, 2023

Particulars	Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment			
(b) Intangible Assets			
(c) Capital Work in Progress			
(d) Right -Of- Use Assets			
(e) Financial Assets			
i. Investments			
ii. Other Financial Assets			
(f) Other Non-Current Assets	267.78	-0.59	267.18
(g) Deferred Tax Assets (Net)	4.04	0.15	4.19
Total Non Current Assets	271.81		271.37
Current assets			
(a) Inventories			
(b) Financial Assets			
(i) Trade Receivables	115.00	-	115.00
(ii) Cash and Cash Equivalents	0.35	-	0.35
(iii) Bank Balances Other than (ii) above			
(c) Other Current Assets			
Total Current Assets	115.35		115.35
Total Assets	387.16		386.72



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of Equity March 31, 2023

Particulars	Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Equity and Liabilities			
Equity			
(a) Equity Share capital	20.00	-	20.00
(b) Other Equity	17.47	-0.45	17.02
Total Equity	37.47		37.02
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities			
Borrowings			
Lease liabilities			
Other Financial Liability			
(b) Provisions			
(c) Deferred Tax liabilities (Net)			
Total Non Current Liabilities			
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings			
(ii) Lease liabilities			
(iii) Trade Payables			
Total outstanding dues of micro enterprises and small enterprises			
Total outstanding dues of creditors other than micro enterprises and small enterprise	346.75		346.75
(iv) Other Financial Liabilities	-		
(b) Other Current Liabilities	2.94		2.94
(c) Provision	-		-
(d) Current Tax Liabilities (Net)			
Total Current Liabilities	349.69		349.69
Total Liabilities	349.69		349.69
Total Equity and Liabilities	387.16		386.72



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of total comprehensive income for the year ended 31 March 2023

Particulars	Regrouped & Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Income			
Revenue from operations (net)			
Other income	0.01		0.01
Total Income (I)	0.01		0.01
Expenses			
Cost of materials consumed			
Purchase of Traded Goods			
Changes in stock of finished goods, work in progress			
Employee benefits expense			
Finance costs			
Depreciation expense			
Other expenses	0.63		0.63
Total Expenses (II)	0.63		0.63
Profit before exceptional items and tax (I-II)	-0.62		-0.62
Exceptional Items			
Profit before tax	-0.62		-0.62
Tax expense:			
Current tax			
MAT			
Deferred tax			
Total Tax expense			
Profit for the year	-0.62		-0.62
Other Comprehensive Income			
A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:			
Remeasurement of gains (losses) on defined benefit plans			
Income tax effect			
Total Other Comprehensive Income			
Total Comprehensive Income For The Period	-0.62		-0.62



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

2.3 Reconciliations between previous GAAP and Ind AS

Ind AS 101 requires an entity to reconcile equity and total comprehensive income prior periods. The following tables represent the reconciliations from previous GAAP to Ind AS.

The presentation requirements under previous GAAP differs from Ind AS and hence the previous GAAP information has been regrouped for ease of reconciliation with Ind AS. The regrouped previous GAAP information is derived based on the audited financial statements of the Company for the year ended 31 March 2022.

Reconciliation of Equity at 31 March 2022

Particulars	Restated as per previous GAAP	Effects of transition to Ind-AS	Ind AS
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	267.18		267.18
(b) Intangible Assets			
(c) Capital Work in Progress			
(d) Right -Of- Use Assets			
(e) Financial Assets			
i. Investments			
ii. Other Financial Assets			
(f) Other Non-Current Assets	0.59	-0.59	
(g) Deferred Tax Assets (Net)	4.04	0.15	4.19
Total Non Current Assets	271.81		271.37
Current assets			
(a) Inventories			
(b) Financial Assets			
(i) Trade Receivables	116.07		116.07
(ii) Cash and Cash Equivalents	0.34		0.34
(iii) Bank Balances Other than (ii) above			
(c) Other Current Assets			
Total Current Assets	116.41		116.41
Total Assets	388.22		387.77



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of Equity at 31 March 2022

Particulars	Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Equity and Liabilities			
Equity			
(a) Equity Share capital	20.00	-	20.00
(b) Other Equity	18.09	-0.45	17.65
Total Equity	38.09		37.65
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities			
Borrowings			
Lease liabilities			
Other Financial Liability			
(b) Provisions			
(c) Deferred Tax liabilities (Net)			
Total Non Current Liabilities			
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings			
(ii) Lease liabilities			
(iii) Trade Payables			
Total outstanding dues of micro enterprises and small enterprises			
Total outstanding dues of creditors other than micro enterprises and small enterprise	346.72		346.72
(iv) Other Financial Liabilities	-		
(b) Other Current Liabilities	2.92		2.92
(c) Provision	-		-
(d) Current Tax Liabilities (Net)	0.49		0.49
Total Current Liabilities	350.13		350.13
Total Liabilities	350.13		350.13
Total Equity and Liabilities	388.22		387.77



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of total comprehensive income for the year ended 31 March 2022

Particulars	Regrouped & Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Income			
Revenue from operations (net)	-		-
Other income	78.60		78.60
Total Income (I)	78.60		78.60
Expenses			
Cost of materials consumed			
Purchase of Traded Goods			
Changes in stock of finished goods, work in progress			
Employee benefits expense	4.80	-	4.80
Finance costs	-	-	-
Depreciation expense	57.40	-	57.40
Other expenses	2.93	-0.20	2.73
Total Expenses (II)	65.13		64.93
Profit before exceptional items and tax (I-II)	13.47		13.67
Exceptional Items			
Profit before tax	13.47		13.67
Tax expense:			
Current tax	5.49	-	5.49
MAT	-	-	-
Deferred tax	-1.87	0.05	-1.82
Total Tax expense	3.62		3.67
Profit for the year	9.85		10.00
Other Comprehensive Income			
A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:			
Remeasurement of gains (losses) on defined benefit plans			
Income tax effect			
Total Other Comprehensive Income			
Total Comprehensive Income For The Period	9.85		10.00



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

2.4 Reconciliations between previous GAAP and Ind AS

Ind AS 101 requires an entity to reconcile equity and total comprehensive income prior periods. The following tables represent the reconciliations from previous GAAP to Ind AS.

The presentation requirements under previous GAAP differs from Ind AS and hence the previous GAAP information has been regrouped for ease of reconciliation with Ind AS. The regrouped previous GAAP information is derived based on the audited financial statements of the Company for the year ended 01 April 2021.

Reconciliation of Equity at 01 April 2021

Particulars	Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	324.58		324.58
(b) Intangible Assets			
(c) Capital Work in Progress			
(d) Right -Of- Use Assets			
(e) Financial Assets			
i. Investments			
ii. Other Financial Assets			
(f) Other Non-Current Assets	0.79	-0.79	
(g) Deferred Tax Assets (Net)	2.17	0.20	2.37
Total Non Current Assets	327.54		326.95
Current assets			
(a) Inventories			
(b) Financial Assets			
(i) Trade Receivables	55.38		55.38
(ii) Cash and Cash Equivalents	0.11		0.11
(iii) Bank Balances Other than (ii) above			
(c) Other Current Assets			
Total Current Assets	55.49		55.49
Total Assets	383.03		382.44



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of Equity at 01 April 2021

Particulars	Restated as per previous GAAP	Effects of transition to Ind- AS	Ind AS
Equity and Liabilities			
Equity			
(a) Equity Share capital	20.00	-	20.00
(b) Other Equity	8.24	-0.59	7.65
Total Equity	28.24		27.65
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities			
Borrowings			
Lease liabilities			
Other Financial Liability			
(b) Provisions			
(c) Deferred Tax liabilities (Net)			
Total Non Current Liabilities			
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings			
(ii) Lease liabilities			
(iii) Trade Payables			
Total outstanding dues of micro enterprises and small enterprises			
Total outstanding dues of creditors other than micro enterprises and small enterprise	344.76		344.76
(iv) Other Financial Liabilities	-		
(b) Other Current Liabilities	5.10		5.10
(c) Provision	-		-
(d) Current Tax Liabilities (Net)	4.93		4.93
Total Current Liabilities	354.79		354.79
Total Liabilities	354.79		354.79
Total Equity and Liabilities	383.03		382.44



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED**Notes forming part of the Restated Consolidated Financial Information**

(All amounts are ₹ in Lakhs, unless otherwise stated)

Reconciliation of total equity as at 31 March 2024, 31 March 2023 and 31 March 2022

Particulars	31 March 2024	31 March 2023	31 March 2022	01 April 2021
Total equity (shareholder's funds) as per previous GAAP	1,089.20	36.97	38.09	28.24
Adjustments				
RFS Adjustment (Previous Periods)	-0.45	-0.45	-0.59	-
On Derecognition of Asset (Preliminary Expense)	-		-	-0.79
Reversal of Pre-operative expense	0.15		0.20	
Adoption of Ind AS 116	-6.96			
Reversal of Rent Expenses	5.05			
Amortization of prepaid lease rent	-0.07			
Interest income (unwinding of discount)	0.05			
Accounting Adjustments	-			
Deferred Tax	-6.54		-0.05	0.20
Total Adjustments	-8.77	-0.45	-0.44	-0.59
Total equity as per Ind AS	1,080.42	36.52	37.65	27.65

Reconciliation of total comprehensive income for the year ended 31 March 2024, 31 March 2023 and 31 March 2022

Particulars	31 March 2024	31 March 2023	31 March 2022
Profit/(Loss) after tax as per previous	145.36	-0.62	9.85
Adjustments			
Reversal of Pre-operative expense	0.15		0.20
Adoption of Ind AS 116	-6.96		
Reversal of Rent Expenses	5.05		
Amortization of prepaid rent	-0.07		
Interest income (unwinding of discount)	0.05		
Accounting Adjustments	34.37		
Deferred Tax	-6.54	-	-0.05
Total Adjustments	26.04	-	0.15
Profit after tax as per Ind AS	171.40	-0.62	10.00
Other Comprehensive Income	-	-	-
Total Comprehensive Income as per Ind AS	171.40	-0.62	10.00



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

3 Notes to first-time adoption:

3.1 Property, plant and equipment

Under previous GAAP, property, plant and equipment were carried at cost less accumulated depreciation and impairment, if any. On transition to Ind AS, the company has opted to continue with the carrying value for all of its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind ASs, measured as per the previous GAAP and use that as its deemed cost as at the date of transition.

This option has also be availed for intangible assets covered by Ind AS 38, Intangible Assets.

3.2 Borrowing at amortised cost

Under previous GAAP, transaction cost (upfront fee) for borrowings taken for working capital/fixed assets were charged to profit or loss account as one time expenses. These costs are recognised in the profit or loss over the tenure of the borrowing as part of the interest expense by applying the Straight line method.

3.3 Expected Credit Loss

Under the previous GAAP, the Company use to measure provision on doubtful debts based on estimate. Ind AS requires that the company to recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

3.4 Remeasurements of post-employment benefit obligations

Under Ind AS, remeasurements i.e. actuarial gains and losses and the return on plan assets, excluding amounts included in the net interest expense on the net defined benefit liability are recognised in other comprehensive income instead of profit or loss. Under the previous GAAP, these remeasurements (if any) were forming part of the profit or loss for the year.

3.5 Deferred Tax

Under previous GAAP, deferred taxes were recognised for the tax effects of timing differences between accounting profit and taxable profit for the year using the income statement approach. Under Ind AS, deferred taxes are required to be recognised using the balance sheet approach for future tax consequences of temporary differences between the carrying value of assets and liabilities and their respective tax bases.

3.6 Retained earnings

Retained earnings as at 01 April 2021 has been adjusted consequent to the above Ind AS transition adjustments.



GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Notes forming part of the Restated Consolidated Financial Information

3.7 Other comprehensive income

Under Ind AS, all items of income and expense recognised in a period should be included in profit or loss for the period, unless a standard requires or permits otherwise. Items of income and expense that are not recognised in profit or loss but are shown in the statement of profit and loss as 'other comprehensive income' includes remeasurements of defined benefit plans. The concept of other comprehensive income did not exist under previous GAAP.

3.8 Right to use asset

Ind AS 116 require a lessee to recognise assets and liabilities for all leases subject to recognition exemptions.

Thus, Right of use asset is recognised at cost which includes present Value of lease payments adjusted for any payments made on or before the commencement of lease and initial direct cost, if any. It is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. Right of use asset is depreciated using straight line method from the commencement date over the earlier of useful life of the asset or the lease term.

Similarly, Lease liability is recognised at the present value of lease payments that are not made at the commencement of lease or transition date whichever is later. Lease liability is subsequently measured by adjusting carrying amount to reflect interest, lease payments and remeasurement, if any.


3.9 Fair valuation of security deposits

Under the previous GAAP, the Company had accounted for security deposits at the undiscounted value. In contrast, Ind AS require the where the effect of time value of money is material, the amount of security deposits should be the present value of the amount expected to be received. The difference arising out of such discounting as at the date of transition has been adjusted against retained earnings.


For & on Behalf of
Y M SHAH & Co.
Chartered Accountants
FRN: 114124W


CA Yogesh Shah
Partner

Membership No. 044305
UDIN: 25044305BMOQMP1038
Place: Vadodara
Date: 15-03-2025



For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
CIN: U85300GJ2019PLC111559


Pragnesh Bharpoda
Director
DIN: 01033141


Niki Tiwari
Company Secretary


Anitaben Bharpoda
Director
DIN: 08644747


Bhavikaben Patel
Chief Financial Officer

